#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-6	Sexual	_
1-2	7-13	trauma	_
1-3	14-21	history	_
1-4	22-24	is	_
1-5	25-35	associated	_
1-6	36-40	with	_
1-7	41-48	reduced	_
1-8	49-62	orbitofrontal	_
1-9	63-70	network	_
1-10	71-79	strength	_
1-11	80-82	in	_
1-12	83-102	substance-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
1-13	103-108	women	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
1-14	109-112	Aim	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-15	113-122	Substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-16	123-126	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-17	127-136	disorders	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-18	137-138	(	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-19	139-143	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-20	144-145	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-21	146-149	are	_
1-22	150-156	highly	_
1-23	157-165	comorbid	_
1-24	166-170	with	_
1-25	171-185	post-traumatic	_
1-26	186-192	stress	http://maven.renci.org/NeuroBridge/neurobridge#AcuteStressDisorder
1-27	193-201	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AcuteStressDisorder
1-28	202-203	(	http://maven.renci.org/NeuroBridge/neurobridge#AcuteStressDisorder
1-29	204-208	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#AcuteStressDisorder
1-30	209-210	)	http://maven.renci.org/NeuroBridge/neurobridge#AcuteStressDisorder
1-31	211-212	.	_

2-1	213-221	PTSD-SUD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
2-2	222-233	comorbidity	_
2-3	234-236	is	_
2-4	237-247	associated	_
2-5	248-252	with	_
2-6	253-260	greater	_
2-7	261-271	functional	_
2-8	272-283	impairments	_
2-9	284-287	and	_
2-10	288-295	relapse	_
2-11	296-300	risk	_
2-12	301-302	.	_

3-1	303-308	Women	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
3-2	309-313	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
3-3	314-318	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
3-4	319-329	experience	_
3-5	330-338	markedly	_
3-6	339-345	higher	_
3-7	346-351	rates	_
3-8	352-354	of	_
3-9	355-361	trauma	_
3-10	362-365	and	_
3-11	366-370	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
3-12	371-379	compared	_
3-13	380-382	to	_
3-14	383-386	men	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
3-15	387-391	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
3-16	392-396	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
3-17	397-398	,	_
3-18	399-411	particularly	_
3-19	412-415	due	_
3-20	416-418	to	_
3-21	419-425	sexual	_
3-22	426-429	and	_
3-23	430-438	domestic	_
3-24	439-444	abuse	_
3-25	445-446	.	_

4-1	447-454	Despite	_
4-2	455-458	the	_
4-3	459-465	strong	_
4-4	466-477	association	_
4-5	478-485	between	_
4-6	486-492	trauma	_
4-7	493-501	exposure	_
4-8	502-505	and	_
4-9	506-510	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-10	511-512	,	_
4-11	513-516	the	_
4-12	517-532	neurobiological	_
4-13	533-543	correlates	_
4-14	544-547	are	_
4-15	548-560	understudied	_
4-16	561-562	,	_
4-17	563-575	particularly	_
4-18	576-581	among	_
4-19	582-589	females	_
4-20	590-594	with	_
4-21	595-599	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-22	600-601	.	_

5-1	602-609	However	_
5-2	610-611	,	_
5-3	612-617	there	_
5-4	618-620	is	_
5-5	621-631	indication	_
5-6	632-634	of	_
5-7	635-643	abnormal	_
5-8	644-651	somatic	_
5-9	652-655	and	_
5-10	656-669	interoceptive	_
5-11	670-680	processing	_
5-12	681-683	in	_
5-13	684-689	women	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
5-14	690-694	with	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
5-15	695-699	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
5-16	700-701	.	_

6-1	702-705	The	_
6-2	706-713	present	_
6-3	714-719	study	_
6-4	720-728	examines	_
6-5	729-749	interoception-linked	_
6-6	750-761	differences	_
6-7	762-764	in	_
6-8	765-774	intrinsic	_
6-9	775-780	brain	_
6-10	781-789	networks	_
6-11	790-792	in	_
6-12	793-794	a	_
6-13	795-800	group	_
6-14	801-803	of	_
6-15	804-809	women	_
6-16	810-814	with	_
6-17	815-819	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-18	820-823	and	_
6-19	824-831	varying	_
6-20	832-841	histories	_
6-21	842-844	of	_
6-22	845-851	trauma	_
6-23	852-860	exposure	_
6-24	861-862	,	_
6-25	863-867	some	_
6-26	868-870	of	_
6-27	871-875	whom	_
6-28	876-880	have	_
6-29	881-882	a	_
6-30	883-890	current	_
6-31	891-895	PTSD	_
6-32	896-905	diagnosis	_
6-33	906-907	.	_

7-1	908-915	Methods	_
7-2	916-932	Pre-intervention	_
7-3	933-937	data	_
7-4	938-942	were	_
7-5	943-951	analyzed	_
7-6	952-956	from	_
7-7	957-958	a	_
7-8	959-965	subset	_
7-9	966-967	(	_
7-10	968-969	N	_
7-11	970-971	=	_
7-12	972-974	43	_
7-13	975-976	)	_
7-14	977-979	of	_
7-15	980-985	women	_
7-16	986-988	in	_
7-17	989-992	SUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
7-18	993-1004	residential	_
7-19	1005-1014	treatment	_
7-20	1015-1024	recruited	_
7-21	1025-1028	for	_
7-22	1029-1030	a	_
7-23	1031-1048	mindfulness-based	_
7-24	1049-1061	intervention	_
7-25	1062-1070	efficacy	_
7-26	1071-1079	clinical	_
7-27	1080-1085	trial	_
7-28	1086-1087	.	_

8-1	1088-1100	Participants	_
8-2	1101-1110	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
8-3	1111-1115	with	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
8-4	1116-1120	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
8-5	1121-1122	(	_
8-6	1123-1124	n	_
8-7	1125-1126	=	_
8-8	1127-1129	14	_
8-9	1130-1131	)	_
8-10	1132-1134	or	_
8-11	1135-1138	not	_
8-12	1139-1140	(	_
8-13	1141-1142	n	_
8-14	1143-1144	=	_
8-15	1145-1147	29	_
8-16	1148-1149	)	_
8-17	1150-1159	performed	_
8-18	1160-1161	a	_
8-19	1162-1166	task	_
8-20	1167-1172	which	_
8-21	1173-1181	involved	_
8-22	1182-1191	attending	_
8-23	1192-1194	to	_
8-24	1195-1198	the	_
8-25	1199-1206	somatic	_
8-26	1207-1210	and	_
8-27	1211-1219	visceral	_
8-28	1220-1230	sensations	_
8-29	1231-1233	of	_
8-30	1234-1237	the	_
8-31	1238-1247	breathing	_
8-32	1248-1253	cycle	_
8-33	1254-1255	(	_
8-34	1256-1269	interoception	_
8-35	1270-1271	)	_
8-36	1272-1277	while	_
8-37	1278-1288	undergoing	_
8-38	1289-1290	a	_
8-39	1291-1301	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
8-40	1302-1305	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
8-41	1306-1307	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
8-42	1308-1312	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
8-43	1313-1314	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
8-44	1315-1319	scan	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalCapacityRatingScale
8-45	1320-1321	.	_

9-1	1322-1326	FMRI	_
9-2	1327-1335	analysis	_
9-3	1336-1344	employed	_
9-4	1345-1356	independent	_
9-5	1357-1367	components	_
9-6	1368-1376	analysis	_
9-7	1377-1380	and	_
9-8	1381-1385	dual	_
9-9	1386-1396	regression	_
9-10	1397-1398	.	_

10-1	1399-1404	First	_
10-2	1405-1406	,	_
10-3	1407-1409	we	_
10-4	1410-1418	assessed	_
10-5	1419-1430	differences	_
10-6	1431-1433	in	_
10-7	1434-1444	functional	_
10-8	1445-1457	connectivity	_
10-9	1458-1460	of	_
10-10	1461-1484	interoception-modulated	_
10-11	1485-1495	functional	_
10-12	1496-1504	networks	_
10-13	1505-1510	among	_
10-14	1511-1516	those	_
10-15	1517-1521	with	_
10-16	1522-1525	and	_
10-17	1526-1533	without	_
10-18	1534-1538	PTSD	_
10-19	1539-1540	.	_

11-1	1541-1547	Second	_
11-2	1548-1549	,	_
11-3	1550-1552	we	_
11-4	1553-1559	tested	_
11-5	1560-1572	associations	_
11-6	1573-1580	between	_
11-7	1581-1588	network	_
11-8	1589-1597	strength	_
11-9	1598-1601	and	_
11-10	1602-1610	lifetime	_
11-11	1611-1617	sexual	_
11-12	1618-1626	violence	_
11-13	1627-1635	exposure	_
11-14	1636-1642	across	_
11-15	1643-1646	all	_
11-16	1647-1659	participants	_
11-17	1660-1662	on	_
11-18	1663-1671	networks	_
11-19	1672-1676	that	_
11-20	1677-1683	showed	_
11-21	1684-1695	significant	_
11-22	1696-1701	group	_
11-23	1702-1713	differences	_
11-24	1714-1715	.	_

12-1	1716-1723	Results	_
12-2	1724-1728	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
12-3	1729-1738	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
12-4	1739-1742	was	_
12-5	1743-1753	associated	_
12-6	1754-1758	with	_
12-7	1759-1766	reduced	_
12-8	1767-1777	functional	_
12-9	1778-1790	connectivity	_
12-10	1791-1793	of	_
12-11	1794-1796	an	_
12-12	1797-1810	orbitofrontal	_
12-13	1811-1818	network	_
12-14	1819-1823	with	_
12-15	1824-1827	the	_
12-16	1828-1837	precuneus	_
12-17	1838-1839	,	_
12-18	1840-1853	mid-posterior	_
12-19	1854-1860	insula	_
12-20	1861-1862	,	_
12-21	1863-1870	lateral	_
12-22	1871-1881	prefrontal	_
12-23	1882-1888	cortex	_
12-24	1889-1892	and	_
12-25	1893-1900	angular	_
12-26	1901-1906	gyrus	_
12-27	1907-1908	.	_

13-1	1909-1912	OFC	_
13-2	1913-1920	network	_
13-3	1921-1929	strength	_
13-4	1930-1933	was	_
13-5	1934-1943	inversely	_
13-6	1944-1954	associated	_
13-7	1955-1959	with	_
13-8	1960-1966	sexual	_
13-9	1967-1975	violence	_
13-10	1976-1984	exposure	_
13-11	1985-1999	over-and-above	_
13-12	2000-2003	the	_
13-13	2004-2016	contribution	_
13-14	2017-2019	of	_
13-15	2020-2024	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
13-16	2025-2031	status	_
13-17	2032-2037	alone	_
13-18	2038-2039	.	_

14-1	2040-2051	Conclusions	_
14-2	2052-2055	Our	_
14-3	2056-2064	findings	_
14-4	2065-2072	provide	_
14-5	2073-2074	a	_
14-6	2075-2080	novel	_
14-7	2081-2094	network-level	_
14-8	2095-2102	account	_
14-9	2103-2105	of	_
14-10	2106-2111	brain	_
14-11	2112-2120	activity	_
14-12	2121-2131	associated	_
14-13	2132-2136	with	_
14-14	2137-2141	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
14-15	2142-2147	among	_
14-16	2148-2153	women	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
14-17	2154-2158	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
14-18	2159-2163	SUDs	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
14-19	2164-2165	,	_
14-20	2166-2171	which	_
14-21	2172-2175	may	_
14-22	2176-2182	inform	_
14-23	2183-2192	treatment	_
14-24	2193-2201	response	_
14-25	2202-2204	in	_
14-26	2205-2209	this	_
14-27	2210-2223	subpopulation	_
14-28	2224-2225	.	_

15-1	2226-2236	Highlights	_
15-2	2237-2241	FMRI	_
15-3	2242-2252	correlates	_
15-4	2253-2255	of	_
15-5	2256-2269	interoceptive	_
15-6	2270-2279	attention	_
15-7	2280-2282	in	_
15-8	2283-2288	women	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
15-9	2289-2293	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
15-10	2294-2303	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
15-11	2304-2307	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
15-12	2308-2316	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
15-13	2317-2318	(	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
15-14	2319-2322	SUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
15-15	2323-2324	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
15-16	2325-2328	and	_
15-17	2329-2343	post-traumatic	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
15-18	2344-2350	stress	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
15-19	2351-2352	(	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
15-20	2353-2357	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
15-21	2358-2359	)	_
15-22	2360-2370	Task-based	_
15-23	2371-2375	data	_
15-24	2376-2384	analyzed	_
15-25	2385-2390	using	_
15-26	2391-2402	independent	_
15-27	2403-2413	components	_
15-28	2414-2422	analysis	_
15-29	2423-2426	and	_
15-30	2427-2431	dual	_
15-31	2432-2442	regression	_
15-32	2443-2450	Reduced	_
15-33	2451-2464	orbitofrontal	_
15-34	2465-2472	network	_
15-35	2473-2485	connectivity	_
15-36	2486-2490	with	_
15-37	2491-2497	insula	_
15-38	2498-2501	and	_
15-39	2502-2516	frontoparietal	_
15-40	2517-2524	regions	_
15-41	2525-2527	in	_
15-42	2528-2536	SUD_PTSD	_
15-43	2537-2548	comorbidity	_
15-44	2549-2557	compared	_
15-45	2558-2560	to	_
15-46	2561-2564	SUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
15-47	2565-2575	Functional	_
15-48	2576-2584	networks	_
15-49	2585-2595	associated	_
15-50	2596-2600	with	_
15-51	2601-2614	exteroception	_
15-52	2615-2618	did	_
15-53	2619-2622	not	_
15-54	2623-2634	distinguish	_
15-55	2635-2643	PTSD-SUD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
15-56	2644-2648	from	_
15-57	2649-2657	SUD-only	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
15-58	2658-2666	Severity	_
15-59	2667-2669	of	_
15-60	2670-2676	sexual	_
15-61	2677-2683	trauma	_
15-62	2684-2692	exposure	_
15-63	2693-2695	is	_
15-64	2696-2705	inversely	_
15-65	2706-2716	associated	_
15-66	2717-2721	with	_
15-67	2722-2735	orbitofrontal	_
15-68	2736-2743	network	_
15-69	2744-2752	strength	_
15-70	2753-2759	beyond	_
15-71	2760-2764	PTSD	_
15-72	2765-2771	status	_
15-73	2772-2779	Methods	_
15-74	2780-2792	Participants	_
15-75	2793-2796	The	_
15-76	2797-2801	full	_
15-77	2802-2808	sample	_
15-78	2809-2811	of	_
15-79	2812-2824	participants	_
15-80	2825-2829	were	_
15-81	2830-2832	48	_
15-82	2833-2851	ethnically-diverse	_
15-83	2852-2853	,	_
15-84	2854-2872	socio-economically	_
15-85	2873-2886	disadvantaged	_
15-86	2887-2893	female	_
15-87	2894-2902	patients	_
15-88	2903-2913	initiating	_
15-89	2914-2924	women-only	_
15-90	2925-2936	residential	_
15-91	2937-2946	treatment	_
15-92	2947-2950	for	_
15-93	2951-2964	polysubstance	_
15-94	2965-2968	use	_
15-95	2969-2978	disorders	_
15-96	2979-2980	(	_
15-97	2981-2990	primarily	_
15-98	2991-3009	moderate-to-severe	_
15-99	3010-3025	methamphetamine	_
15-100	3026-3032	and/or	_
15-101	3033-3040	cocaine	_
15-102	3041-3044	use	_
15-103	3045-3054	disorders	_
15-104	3055-3056	)	_
15-105	3057-3058	.	_

16-1	3059-3068	Inclusion	_
16-2	3069-3077	criteria	_
16-3	3078-3081	for	_
16-4	3082-3085	the	_
16-5	3086-3091	study	_
16-6	3092-3096	were	_
16-7	3097-3099	as	_
16-8	3100-3107	follows	_
16-9	3108-3109	:	_
16-10	3110-3116	female	_
16-11	3117-3118	,	_
16-12	3119-3126	between	_
16-13	3127-3129	18	_
16-14	3130-3133	and	_
16-15	3134-3136	50	_
16-16	3137-3142	years	_
16-17	3143-3146	old	_
16-18	3147-3148	,	_
16-19	3149-3158	diagnosed	_
16-20	3159-3163	with	_
16-21	3164-3167	SUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
16-22	3168-3169	,	_
16-23	3170-3176	fluent	_
16-24	3177-3179	in	_
16-25	3180-3187	English	_
16-26	3188-3189	,	_
16-27	3190-3202	right-handed	_
16-28	3203-3204	,	_
16-29	3205-3208	and	_
16-30	3209-3210	a	_
16-31	3211-3218	current	_
16-32	3219-3226	patient	_
16-33	3227-3229	in	_
16-34	3230-3233	the	_
16-35	3234-3245	residential	_
16-36	3246-3255	treatment	_
16-37	3256-3263	program	_
16-38	3264-3273	partnered	_
16-39	3274-3278	with	_
16-40	3279-3282	the	_
16-41	3283-3289	parent	_
16-42	3290-3295	study	_
16-43	3296-3297	.	_

17-1	3298-3307	Exclusion	_
17-2	3308-3316	criteria	_
17-3	3317-3325	included	_
17-4	3326-3343	contraindications	_
17-5	3344-3347	for	_
17-6	3348-3352	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
17-7	3353-3354	:	_
17-8	3355-3364	currently	_
17-9	3365-3367	or	_
17-10	3368-3376	possibly	_
17-11	3377-3385	pregnant	_
17-12	3386-3387	,	_
17-13	3388-3393	using	_
17-14	3394-3401	medical	_
17-15	3402-3409	devices	_
17-16	3410-3411	(	_
17-17	3412-3419	cardiac	_
17-18	3420-3429	pacemaker	_
17-19	3430-3431	,	_
17-20	3432-3441	implanted	_
17-21	3442-3449	cardiac	_
17-22	3450-3463	defibrillator	_
17-23	3464-3465	,	_
17-24	3466-3469	etc	_
17-25	3470-3471	.	_

18-1	3472-3473	)	_
18-2	3474-3475	,	_
18-3	3476-3481	metal	_
18-4	3482-3491	fragments	_
18-5	3492-3501	including	_
18-6	3502-3510	shrapnel	_
18-7	3511-3513	or	_
18-8	3514-3519	other	_
18-9	3520-3532	nonremovable	_
18-10	3533-3538	metal	_
18-11	3539-3546	devices	_
18-12	3547-3556	including	_
18-13	3557-3563	dental	_
18-14	3564-3570	braces	_
18-15	3571-3573	or	_
18-16	3574-3583	retainers	_
18-17	3584-3585	,	_
18-18	3586-3598	intrauterine	_
18-19	3599-3605	device	_
18-20	3606-3607	,	_
18-21	3608-3615	history	_
18-22	3616-3618	of	_
18-23	3619-3623	head	_
18-24	3624-3630	trauma	_
18-25	3631-3640	resulting	_
18-26	3641-3643	in	_
18-27	3644-3648	loss	_
18-28	3649-3651	of	_
18-29	3652-3665	consciousness	_
18-30	3666-3669	for	_
18-31	3670-3671	>	_
18-32	3672-3673	5	_
18-33	3674-3677	min	_
18-34	3678-3679	,	_
18-35	3680-3690	documented	_
18-36	3691-3693	or	_
18-37	3694-3706	subjectively	_
18-38	3707-3715	reported	_
18-39	3716-3730	claustrophobia	_
18-40	3731-3732	,	_
18-41	3733-3737	hair	_
18-42	3738-3748	extensions	_
18-43	3749-3751	or	_
18-44	3752-3753	a	_
18-45	3754-3757	wig	_
18-46	3758-3767	connected	_
18-47	3768-3770	by	_
18-48	3771-3775	wire	_
18-49	3776-3777	,	_
18-50	3778-3787	permanent	_
18-51	3788-3796	eyeliner	_
18-52	3797-3798	,	_
18-53	3799-3802	and	_
18-54	3803-3806	BMI	_
18-55	3807-3808	>	_
18-56	3809-3811	36	_
18-57	3812-3813	.	_

19-1	3814-3826	Additionally	_
19-2	3827-3828	,	_
19-3	3829-3841	participants	_
19-4	3842-3846	were	_
19-5	3847-3855	excluded	_
19-6	3856-3860	from	_
19-7	3861-3864	the	_
19-8	3865-3871	parent	_
19-9	3872-3877	study	_
19-10	3878-3880	if	_
19-11	3881-3885	they	_
19-12	3886-3889	had	_
19-13	3890-3892	an	_
19-14	3893-3902	untreated	_
19-15	3903-3909	severe	_
19-16	3910-3917	chronic	_
19-17	3918-3924	mental	_
19-18	3925-3931	health	_
19-19	3932-3941	condition	_
19-20	3942-3944	or	_
19-21	3945-3954	untreated	_
19-22	3955-3964	psychotic	_
19-23	3965-3973	disorder	_
19-24	3974-3979	based	_
19-25	3980-3982	on	_
19-26	3983-3991	clinical	_
19-27	3992-3998	intake	_
19-28	3999-4008	LR-DSM-IV	_
19-29	4009-4011	or	_
19-30	4012-4017	DSM-V	_
19-31	4018-4020	or	_
19-32	4021-4031	diagnostic	_
19-33	4032-4042	assessment	_
19-34	4043-4044	,	_
19-35	4045-4047	or	_
19-36	4048-4056	reported	_
19-37	4057-4068	suicidality	_
19-38	4069-4075	during	_
19-39	4076-4079	the	_
19-40	4080-4085	prior	_
19-41	4086-4088	30	_
19-42	4089-4093	days	_
19-43	4094-4099	based	_
19-44	4100-4102	on	_
19-45	4103-4111	clinical	_
19-46	4112-4118	intake	_
19-47	4119-4129	assessment	_
19-48	4130-4131	.	_

20-1	4132-4143	Psychiatric	_
20-2	4144-4153	diagnoses	_
20-3	4154-4158	were	_
20-4	4159-4164	based	_
20-5	4165-4167	on	_
20-6	4168-4177	LR-DSM-IV	_
20-7	4178-4180	or	_
20-8	4181-4186	DSM-V	_
20-9	4187-4192	which	_
20-10	4193-4197	were	_
20-11	4198-4207	conducted	_
20-12	4208-4210	by	_
20-13	4211-4216	staff	_
20-14	4217-4219	of	_
20-15	4220-4223	the	_
20-16	4224-4235	residential	_
20-17	4236-4245	treatment	_
20-18	4246-4253	program	_
20-19	4254-4255	(	_
20-20	4256-4259	the	_
20-21	4260-4271	residential	_
20-22	4272-4281	treatment	_
20-23	4282-4289	program	_
20-24	4290-4302	transitioned	_
20-25	4303-4307	from	_
20-26	4308-4311	the	_
20-27	4312-4321	LR-DSM-IV	_
20-28	4322-4324	to	_
20-29	4325-4328	the	_
20-30	4329-4334	DSM-V	_
20-31	4335-4341	during	_
20-32	4342-4345	the	_
20-33	4346-4352	course	_
20-34	4353-4355	of	_
20-35	4356-4359	the	_
20-36	4360-4368	clinical	_
20-37	4369-4374	trial	_
20-38	4375-4376	)	_
20-39	4377-4378	.	_

21-1	4379-4388	Diagnoses	_
21-2	4389-4393	were	_
21-3	4394-4401	carried	_
21-4	4402-4405	out	_
21-5	4406-4408	by	_
21-6	4409-4418	treatment	_
21-7	4419-4425	center	_
21-8	4426-4431	staff	_
21-9	4432-4435	and	_
21-10	4436-4445	confirmed	_
21-11	4446-4448	by	_
21-12	4449-4458	consensus	_
21-13	4459-4466	meeting	_
21-14	4467-4471	with	_
21-15	4472-4475	the	_
21-16	4476-4480	lead	_
21-17	4481-4493	psychiatrist	_
21-18	4494-4495	.	_

22-1	4496-4504	Although	_
22-2	4505-4513	comorbid	_
22-3	4514-4525	psychiatric	_
22-4	4526-4535	diagnoses	_
22-5	4536-4540	were	_
22-6	4541-4544	not	_
22-7	4545-4557	exclusionary	_
22-8	4558-4561	for	_
22-9	4562-4565	the	_
22-10	4566-4572	parent	_
22-11	4573-4578	study	_
22-12	4579-4580	,	_
22-13	4581-4584	for	_
22-14	4585-4588	the	_
22-15	4589-4596	present	_
22-16	4597-4605	analysis	_
22-17	4606-4608	we	_
22-18	4609-4617	excluded	_
22-19	4618-4629	individuals	_
22-20	4630-4634	with	_
22-21	4635-4638	the	_
22-22	4639-4648	following	_
22-23	4649-4658	diagnoses	_
22-24	4659-4660	:	_
22-25	4661-4674	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
22-26	4675-4676	,	_
22-27	4677-4684	anxiety	_
22-28	4685-4693	disorder	_
22-29	4694-4699	other	_
22-30	4700-4704	than	_
22-31	4705-4709	PTSD	_
22-32	4710-4711	,	_
22-33	4712-4714	no	_
22-34	4715-4722	history	_
22-35	4723-4725	of	_
22-36	4726-4735	stimulant	_
22-37	4736-4739	use	_
22-38	4740-4741	(	_
22-39	4742-4745	the	_
22-40	4746-4754	majority	_
22-41	4755-4757	of	_
22-42	4758-4766	patients	_
22-43	4767-4770	had	_
22-44	4771-4780	primarily	_
22-45	4781-4790	diagnoses	_
22-46	4791-4793	of	_
22-47	4794-4803	stimulant	_
22-48	4804-4807	use	_
22-49	4808-4817	disorders	_
22-50	4818-4820	or	_
22-51	4821-4824	had	_
22-52	4825-4838	polysubstance	_
22-53	4839-4842	use	_
22-54	4843-4852	histories	_
22-55	4853-4857	that	_
22-56	4858-4866	included	_
22-57	4867-4877	stimulants	_
22-58	4878-4879	)	_
22-59	4880-4881	.	_

23-1	4882-4886	Four	_
23-2	4887-4899	participants	_
23-3	4900-4904	were	_
23-4	4905-4912	omitted	_
23-5	4913-4918	based	_
23-6	4919-4921	on	_
23-7	4922-4927	these	_
23-8	4928-4936	criteria	_
23-9	4937-4938	.	_

24-1	4939-4940	A	_
24-2	4941-4946	large	_
24-3	4947-4957	proportion	_
24-4	4958-4960	of	_
24-5	4961-4973	participants	_
24-6	4974-4977	for	_
24-7	4978-4982	whom	_
24-8	4983-4994	information	_
24-9	4995-4998	was	_
24-10	4999-5008	available	_
24-11	5009-5013	were	_
24-12	5014-5020	taking	_
24-13	5021-5031	prescribed	_
24-14	5032-5044	psychoactive	_
24-15	5045-5056	medications	_
24-16	5057-5058	(	_
24-17	5059-5063	39.5	_
24-18	5064-5065	%	_
24-19	5066-5067	)	_
24-20	5068-5074	and/or	_
24-21	5075-5078	had	_
24-22	5079-5083	mood	_
24-23	5084-5093	disorders	_
24-24	5094-5095	(	_
24-25	5096-5100	23.3	_
24-26	5101-5102	%	_
24-27	5103-5104	)	_
24-28	5105-5106	,	_
24-29	5107-5116	therefore	_
24-30	5117-5119	we	_
24-31	5120-5123	did	_
24-32	5124-5127	not	_
24-33	5128-5135	exclude	_
24-34	5136-5148	participants	_
24-35	5149-5151	on	_
24-36	5152-5155	the	_
24-37	5156-5161	basis	_
24-38	5162-5164	of	_
24-39	5165-5175	medication	_
24-40	5176-5179	use	_
24-41	5180-5182	or	_
24-42	5183-5196	mood-disorder	_
24-43	5197-5203	status	_
24-44	5204-5205	.	_

25-1	5206-5209	One	_
25-2	5210-5221	participant	_
25-3	5222-5225	was	_
25-4	5226-5233	removed	_
25-5	5234-5238	from	_
25-6	5239-5242	the	_
25-7	5243-5248	study	_
25-8	5249-5252	for	_
25-9	5253-5256	the	_
25-10	5257-5265	presence	_
25-11	5266-5268	of	_
25-12	5269-5282	non-removable	_
25-13	5283-5289	dental	_
25-14	5290-5294	work	_
25-15	5295-5299	that	_
25-16	5300-5303	the	_
25-17	5304-5315	participant	_
25-18	5316-5319	did	_
25-19	5320-5323	not	_
25-20	5324-5330	report	_
25-21	5331-5337	during	_
25-22	5338-5347	screening	_
25-23	5348-5353	which	_
25-24	5354-5360	caused	_
25-25	5361-5367	signal	_
25-26	5368-5375	dropout	_
25-27	5376-5377	.	_

26-1	5378-5381	The	_
26-2	5382-5384	43	_
26-3	5385-5394	remaining	_
26-4	5395-5407	participants	_
26-5	5408-5412	were	_
26-6	5413-5421	included	_
26-7	5422-5424	in	_
26-8	5425-5428	the	_
26-9	5429-5434	study	_
26-10	5435-5436	,	_
26-11	5437-5439	14	_
26-12	5440-5442	of	_
26-13	5443-5447	whom	_
26-14	5448-5451	had	_
26-15	5452-5460	received	_
26-16	5461-5462	a	_
26-17	5463-5467	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
26-18	5468-5477	diagnosis	_
26-19	5478-5479	.	_

27-1	5480-5484	Each	_
27-2	5485-5487	of	_
27-3	5488-5491	the	_
27-4	5492-5494	43	_
27-5	5495-5507	participants	_
27-6	5508-5519	contributed	_
27-7	5520-5523	two	_
27-8	5524-5528	runs	_
27-9	5529-5531	of	_
27-10	5532-5536	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
27-11	5537-5541	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
27-12	5542-5543	,	_
27-13	5544-5550	except	_
27-14	5551-5554	for	_
27-15	5555-5559	four	_
27-16	5560-5568	subjects	_
27-17	5569-5570	(	_
27-18	5571-5574	two	_
27-19	5575-5579	from	_
27-20	5580-5583	the	_
27-21	5584-5588	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
27-22	5589-5590	,	_
27-23	5591-5594	two	_
27-24	5595-5599	from	_
27-25	5600-5603	the	_
27-26	5604-5610	noPTSD	http://maven.renci.org/NeuroBridge/neurobridge#Menopause
27-27	5611-5616	group	_
27-28	5617-5618	)	_
27-29	5619-5622	who	_
27-30	5623-5634	contributed	_
27-31	5635-5638	one	_
27-32	5639-5642	run	_
27-33	5643-5646	due	_
27-34	5647-5649	to	_
27-35	5650-5659	excessive	_
27-36	5660-5666	motion	_
27-37	5667-5668	(	_
27-38	5669-5670	>	_
27-39	5671-5672	3	_
27-40	5673-5675	mm	_
27-41	5676-5677	)	_
27-42	5678-5679	.	_

28-1	5680-5683	See	_
28-2	5684-5689	Table	_
28-3	5690-5691	1	_
28-4	5692-5695	for	_
28-5	5696-5708	demographics	_
28-6	5709-5712	and	_
28-7	5713-5721	clinical	_
28-8	5722-5737	characteristics	_
28-9	5738-5739	.	_

29-1	5740-5743	All	_
29-2	5744-5749	study	_
29-3	5750-5760	procedures	_
29-4	5761-5765	were	_
29-5	5766-5774	approved	_
29-6	5775-5777	by	_
29-7	5778-5781	the	_
29-8	5782-5792	University	_
29-9	5793-5795	of	_
29-10	5796-5804	Southern	_
29-11	5805-5815	California	_
29-12	5816-5829	Institutional	_
29-13	5830-5836	Review	_
29-14	5837-5842	Board	_
29-15	5843-5844	.	_

30-1	5845-5857	Participants	_
30-2	5858-5866	provided	_
30-3	5867-5874	written	_
30-4	5875-5883	informed	_
30-5	5884-5891	consent	_
30-6	5892-5895	and	_
30-7	5896-5900	were	_
30-8	5901-5912	compensated	_
30-9	5913-5916	for	_
30-10	5917-5922	their	_
30-11	5923-5927	time	_
30-12	5928-5929	.	_

31-1	5930-5938	Measures	_
31-2	5939-5943	Life	_
31-3	5944-5953	stressors	_
31-4	5954-5963	checklist	_
31-5	5964-5965	–	_
31-6	5966-5973	revised	_
31-7	5974-5977	The	_
31-8	5978-5982	Life	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
31-9	5983-5991	Stressor	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
31-10	5992-6009	Checklist-Revised	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
31-11	6010-6011	(	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
31-12	6012-6017	LSC-R	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
31-13	6018-6019	)	_
31-14	6020-6022	is	_
31-15	6023-6024	a	_
31-16	6025-6032	measure	_
31-17	6033-6035	of	_
31-18	6036-6045	traumatic	_
31-19	6046-6052	events	_
31-20	6053-6056	and	_
31-21	6057-6066	stressors	_
31-22	6067-6071	that	_
31-23	6072-6075	are	_
31-24	6076-6088	particularly	_
31-25	6089-6097	relevant	_
31-26	6098-6100	to	_
31-27	6101-6106	women	_
31-28	6107-6109	's	_
31-29	6110-6114	life	_
31-30	6115-6126	experiences	_
31-31	6127-6128	.	_

32-1	6129-6132	Its	_
32-2	6133-6136	use	_
32-3	6137-6140	has	_
32-4	6141-6145	been	_
32-5	6146-6155	validated	_
32-6	6156-6158	in	_
32-7	6159-6164	women	_
32-8	6165-6169	with	_
32-9	6170-6179	co-morbid	_
32-10	6180-6189	substance	_
32-11	6190-6195	abuse	_
32-12	6196-6199	and	_
32-13	6200-6206	mental	_
32-14	6207-6216	disorders	_
32-15	6217-6218	,	_
32-16	6219-6223	with	_
32-17	6224-6233	histories	_
32-18	6234-6236	of	_
32-19	6237-6250	interpersonal	_
32-20	6251-6259	violence	_
32-21	6260-6273	victimization	_
32-22	6274-6275	.	_

33-1	6276-6281	LSC-R	_
33-2	6282-6289	follows	_
33-3	6290-6291	a	_
33-4	6292-6298	yes/no	_
33-5	6299-6307	response	_
33-6	6308-6314	format	_
33-7	6315-6319	with	_
33-8	6320-6329	follow-up	_
33-9	6330-6339	questions	_
33-10	6340-6344	that	_
33-11	6345-6357	characterize	_
33-12	6358-6361	the	_
33-13	6362-6366	life	_
33-14	6367-6372	stage	_
33-15	6373-6374	(	_
33-16	6375-6376	s	_
33-17	6377-6378	)	_
33-18	6379-6381	at	_
33-19	6382-6387	which	_
33-20	6388-6394	events	_
33-21	6395-6403	occurred	_
33-22	6404-6407	and	_
33-23	6408-6411	the	_
33-24	6412-6418	degree	_
33-25	6419-6421	to	_
33-26	6422-6427	which	_
33-27	6428-6431	the	_
33-28	6432-6442	respondent	_
33-29	6443-6445	is	_
33-30	6446-6455	currently	_
33-31	6456-6464	affected	_
33-32	6465-6467	by	_
33-33	6468-6471	the	_
33-34	6472-6482	experience	_
33-35	6483-6484	.	_

34-1	6485-6491	Events	_
34-2	6492-6495	can	_
34-3	6496-6498	be	_
34-4	6499-6504	brief	_
34-5	6505-6506	,	_
34-6	6507-6513	single	_
34-7	6514-6523	incidents	_
34-8	6524-6526	or	_
34-9	6527-6535	repeated	_
34-10	6536-6543	traumas	_
34-11	6544-6548	that	_
34-12	6549-6552	may	_
34-13	6553-6557	have	_
34-14	6558-6566	occurred	_
34-15	6567-6569	at	_
34-16	6570-6573	any	_
34-17	6574-6579	point	_
34-18	6580-6582	in	_
34-19	6583-6586	the	_
34-20	6587-6595	lifespan	_
34-21	6596-6597	(	_
34-22	6598-6603	prior	_
34-23	6604-6606	to	_
34-24	6607-6610	age	_
34-25	6611-6619	eighteen	_
34-26	6620-6621	,	_
34-27	6622-6631	adulthood	_
34-28	6632-6633	,	_
34-29	6634-6637	and	_
34-30	6638-6644	within	_
34-31	6645-6648	the	_
34-32	6649-6653	last	_
34-33	6654-6655	8	_
34-34	6656-6662	months	_
34-35	6663-6665	of	_
34-36	6666-6669	the	_
34-37	6670-6679	interview	_
34-38	6680-6681	)	_
34-39	6682-6683	.	_

35-1	6684-6687	For	_
35-2	6688-6691	the	_
35-3	6692-6699	present	_
35-4	6700-6705	study	_
35-5	6706-6707	,	_
35-6	6708-6710	we	_
35-7	6711-6714	use	_
35-8	6715-6728	dichotomously	_
35-9	6729-6735	scored	_
35-10	6736-6745	responses	_
35-11	6746-6747	(	_
35-12	6748-6753	range	_
35-13	6754-6755	:	_
35-14	6756-6760	0–30	_
35-15	6761-6762	)	_
35-16	6763-6773	reflecting	_
35-17	6774-6780	events	_
35-18	6781-6783	at	_
35-19	6784-6787	any	_
35-20	6788-6793	point	_
35-21	6794-6800	during	_
35-22	6801-6804	the	_
35-23	6805-6813	lifespan	_
35-24	6814-6815	.	_

36-1	6816-6825	Addiction	_
36-2	6826-6834	severity	_
36-3	6835-6840	index	_
36-4	6841-6848	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
36-5	6849-6852	and	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
36-6	6853-6862	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
36-7	6863-6866	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale
36-8	6867-6875	severity	_
36-9	6876-6879	for	_
36-10	6880-6883	the	_
36-11	6884-6886	30	_
36-12	6887-6891	days	_
36-13	6892-6897	prior	_
36-14	6898-6900	to	_
36-15	6901-6910	treatment	_
36-16	6911-6916	entry	_
36-17	6917-6920	was	_
36-18	6921-6929	assessed	_
36-19	6930-6935	using	_
36-20	6936-6939	the	_
36-21	6940-6949	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
36-22	6950-6958	Severity	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
36-23	6959-6964	Index	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
36-24	6965-6966	(	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
36-25	6967-6970	ASI	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
36-26	6971-6972	:	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
36-27	6973-6974	)	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
36-28	6975-6978	and	_
36-29	6979-6982	the	_
36-30	6983-6991	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
36-31	6992-7002	Followback	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
36-32	7003-7012	Interview	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
36-33	7013-7014	(	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
36-34	7015-7019	TLFB	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
36-35	7020-7021	)	http://maven.renci.org/NeuroBridge/neurobridge#TimeIntervalUnit
36-36	7022-7023	.	_

37-1	7024-7038	Post-traumatic	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
37-2	7039-7045	stress	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
37-3	7046-7054	disorder	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
37-4	7055-7056	(	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
37-5	7057-7061	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
37-6	7062-7063	)	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
37-7	7064-7072	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
37-8	7073-7078	scale	http://maven.renci.org/NeuroBridge/neurobridge#PosttraumaticStressDisorderSymptomsScale
37-9	7079-7082	The	_
37-10	7083-7087	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
37-11	7088-7095	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
37-12	7096-7101	Scale	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
37-13	7102-7103	(	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
37-14	7104-7109	PSS-I	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
37-15	7110-7111	)	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
37-16	7112-7114	is	_
37-17	7115-7116	a	_
37-18	7117-7132	semi-structured	_
37-19	7133-7142	interview	_
37-20	7143-7144	,	_
37-21	7145-7150	which	_
37-22	7151-7154	was	_
37-23	7155-7159	used	_
37-24	7160-7162	to	_
37-25	7163-7169	obtain	_
37-26	7170-7172	an	_
37-27	7173-7180	overall	_
37-28	7181-7189	severity	_
37-29	7190-7195	score	_
37-30	7196-7198	of	_
37-31	7199-7203	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
37-32	7204-7212	symptoms	_
37-33	7213-7222	according	_
37-34	7223-7225	to	_
37-35	7226-7232	DSM-IV	_
37-36	7233-7234	,	_
37-37	7235-7237	as	_
37-38	7238-7242	well	_
37-39	7243-7245	as	_
37-40	7246-7254	separate	_
37-41	7255-7263	severity	_
37-42	7264-7270	scores	_
37-43	7271-7274	for	_
37-44	7275-7282	symptom	_
37-45	7283-7293	subdomains	_
37-46	7294-7295	:	_
37-47	7296-7311	re-experiencing	_
37-48	7312-7313	,	_
37-49	7314-7323	avoidance	_
37-50	7324-7325	,	_
37-51	7326-7333	arousal	_
37-52	7334-7335	.	_

38-1	7336-7342	Scores	_
38-2	7343-7348	range	_
38-3	7349-7353	from	_
38-4	7354-7355	0	_
38-5	7356-7358	to	_
38-6	7359-7361	34	_
38-7	7362-7363	,	_
38-8	7364-7368	with	_
38-9	7369-7375	higher	_
38-10	7376-7382	scores	_
38-11	7383-7393	reflecting	_
38-12	7394-7398	more	_
38-13	7399-7405	severe	_
38-14	7406-7420	symptomatology	_
38-15	7421-7422	.	_

39-1	7423-7426	The	_
39-2	7427-7454	interoceptive-exteroceptive	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
39-3	7455-7464	attention	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
39-4	7465-7469	task	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
39-5	7470-7473	The	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
39-6	7474-7501	Interoceptive-Exteroceptive	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
39-7	7502-7511	Attention	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
39-8	7512-7516	task	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
39-9	7517-7518	(	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
39-10	7519-7522	The	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
39-11	7523-7529	IN-OUT	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
39-12	7530-7534	task	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
39-13	7535-7536	)	http://maven.renci.org/NeuroBridge/neurobridge#Intervention
39-14	7537-7540	was	_
39-15	7541-7548	adapted	_
39-16	7549-7553	from	_
39-17	7554-7555	,	_
39-18	7556-7561	which	_
39-19	7562-7574	investigated	_
39-20	7575-7579	BOLD	_
39-21	7580-7587	changes	_
39-22	7588-7590	in	_
39-23	7591-7604	interoceptive	_
39-24	7605-7614	attention	_
39-25	7615-7617	in	_
39-26	7618-7626	response	_
39-27	7627-7629	to	_
39-28	7630-7647	Mindfulness-Based	http://maven.renci.org/NeuroBridge/neurobridge#Education
39-29	7648-7654	Stress	http://maven.renci.org/NeuroBridge/neurobridge#Education
39-30	7655-7664	Reduction	http://maven.renci.org/NeuroBridge/neurobridge#Education
39-31	7665-7666	(	http://maven.renci.org/NeuroBridge/neurobridge#Education
39-32	7667-7671	MBSR	http://maven.renci.org/NeuroBridge/neurobridge#Education
39-33	7672-7673	)	http://maven.renci.org/NeuroBridge/neurobridge#Education
39-34	7674-7682	training	http://maven.renci.org/NeuroBridge/neurobridge#Education
39-35	7683-7684	.	_

40-1	7685-7688	The	_
40-2	7689-7697	approach	_
40-3	7698-7707	contrasts	_
40-4	7708-7713	brain	_
40-5	7714-7722	activity	_
40-6	7723-7729	during	_
40-7	7730-7739	attention	_
40-8	7740-7742	to	_
40-9	7743-7746	the	_
40-10	7747-7757	sensations	_
40-11	7758-7760	of	_
40-12	7761-7770	breathing	_
40-13	7771-7777	versus	_
40-14	7778-7787	attention	_
40-15	7788-7790	to	_
40-16	7791-7793	an	_
40-17	7794-7802	external	_
40-18	7803-7809	target	_
40-19	7810-7811	.	_

41-1	7812-7814	By	_
41-2	7815-7826	contrasting	_
41-3	7827-7837	internally	_
41-4	7838-7841	and	_
41-5	7842-7852	externally	_
41-6	7853-7861	directed	_
41-7	7862-7867	focus	_
41-8	7868-7869	,	_
41-9	7870-7874	this	_
41-10	7875-7883	approach	_
41-11	7884-7895	capitalizes	_
41-12	7896-7898	on	_
41-13	7899-7902	the	_
41-14	7903-7904	“	_
41-15	7905-7916	attentional	_
41-16	7917-7926	spotlight	_
41-17	7927-7928	”	_
41-18	7929-7935	effect	_
41-19	7936-7937	,	_
41-20	7938-7945	whereby	_
41-21	7946-7951	focus	_
41-22	7952-7954	on	_
41-23	7955-7956	a	_
41-24	7957-7964	sensory	_
41-25	7965-7972	quality	_
41-26	7973-7982	amplifies	_
41-27	7983-7986	the	_
41-28	7987-7993	signal	_
41-29	7994-8000	within	_
41-30	8001-8006	brain	_
41-31	8007-8014	regions	_
41-32	8015-8025	associated	_
41-33	8026-8030	with	_
41-34	8031-8041	processing	_
41-35	8042-8046	that	_
41-36	8047-8054	sensory	_
41-37	8055-8063	modality	_
41-38	8064-8065	.	_

42-1	8066-8076	Variations	_
42-2	8077-8079	on	_
42-3	8080-8084	this	_
42-4	8085-8089	task	_
42-5	8090-8094	have	_
42-6	8095-8105	previously	_
42-7	8106-8110	been	_
42-8	8111-8115	used	_
42-9	8116-8118	to	_
42-10	8119-8126	isolate	_
42-11	8127-8131	BOLD	_
42-12	8132-8141	responses	_
42-13	8142-8144	in	_
42-14	8145-8152	regions	_
42-15	8153-8163	associated	_
42-16	8164-8168	with	_
42-17	8169-8182	interoception	_
42-18	8183-8185	in	_
42-19	8186-8192	expert	_
42-20	8193-8203	meditators	_
42-21	8204-8205	,	_
42-22	8206-8213	healthy	_
42-23	8214-8225	individuals	_
42-24	8226-8227	,	_
42-25	8228-8230	as	_
42-26	8231-8235	well	_
42-27	8236-8238	as	_
42-28	8239-8241	in	_
42-29	8242-8250	clinical	_
42-30	8251-8262	populations	_
42-31	8263-8267	with	_
42-32	8268-8278	depression	_
42-33	8279-8282	and	_
42-34	8283-8291	anorexia	_
42-35	8292-8299	nervosa	_
42-36	8300-8301	.	_

43-1	8302-8305	The	_
43-2	8306-8315	magnitude	_
43-3	8316-8318	of	_
43-4	8319-8325	insula	_
43-5	8326-8334	response	_
43-6	8335-8341	during	_
43-7	8342-8349	focused	_
43-8	8350-8359	breathing	_
43-9	8360-8365	tasks	_
43-10	8366-8373	appears	_
43-11	8374-8376	to	_
43-12	8377-8382	track	_
43-13	8383-8386	the	_
43-14	8387-8394	quality	_
43-15	8395-8397	of	_
43-16	8398-8406	internal	_
43-17	8407-8412	focus	_
43-18	8413-8414	,	_
43-19	8415-8420	which	_
43-20	8421-8430	increases	_
43-21	8431-8433	as	_
43-22	8434-8435	a	_
43-23	8436-8444	function	_
43-24	8445-8447	of	_
43-25	8448-8453	hours	_
43-26	8454-8463	practiced	_
43-27	8464-8466	in	_
43-28	8467-8474	novices	_
43-29	8475-8478	who	_
43-30	8479-8491	participated	_
43-31	8492-8494	in	_
43-32	8495-8496	a	_
43-33	8497-8514	mindfulness-based	_
43-34	8515-8521	stress	_
43-35	8522-8531	reduction	_
43-36	8532-8533	(	_
43-37	8534-8538	MBSR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
43-38	8539-8540	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
43-39	8541-8548	program	_
43-40	8549-8550	.	_

44-1	8551-8557	During	_
44-2	8558-8561	the	_
44-3	8562-8568	IN-OUT	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
44-4	8569-8573	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
44-5	8574-8586	participants	_
44-6	8587-8596	performed	_
44-7	8597-8600	two	_
44-8	8601-8613	experimental	_
44-9	8614-8624	conditions	_
44-10	8625-8634	involving	_
44-11	8635-8644	sustained	_
44-12	8645-8656	attentional	_
44-13	8657-8664	targets	_
44-14	8665-8666	:	_
44-15	8667-8670	the	_
44-16	8671-8684	interoceptive	_
44-17	8685-8686	(	_
44-18	8687-8689	IN	_
44-19	8690-8691	)	_
44-20	8692-8701	condition	_
44-21	8702-8705	and	_
44-22	8706-8709	the	_
44-23	8710-8723	exteroceptive	_
44-24	8724-8725	(	_
44-25	8726-8729	OUT	_
44-26	8730-8731	)	_
44-27	8732-8741	condition	_
44-28	8742-8743	.	_

45-1	8744-8756	Participants	_
45-2	8757-8766	completed	_
45-3	8767-8770	two	_
45-4	8771-8775	runs	_
45-5	8776-8777	,	_
45-6	8778-8782	each	_
45-7	8783-8793	containing	_
45-8	8794-8798	nine	_
45-9	8799-8805	blocks	_
45-10	8806-8807	.	_

46-1	8808-8811	The	_
46-2	8812-8818	blocks	_
46-3	8819-8823	were	_
46-4	8824-8833	presented	_
46-5	8834-8836	in	_
46-6	8837-8853	pseudorandomized	_
46-7	8854-8860	order-	_
46-8	8861-8865	half	_
46-9	8866-8868	of	_
46-10	8869-8872	the	_
46-11	8873-8877	runs	_
46-12	8878-8887	contained	_
46-13	8888-8892	five	_
46-14	8893-8899	blocks	_
46-15	8900-8902	of	_
46-16	8903-8905	IN	_
46-17	8906-8907	,	_
46-18	8908-8911	and	_
46-19	8912-8916	four	_
46-20	8917-8923	blocks	_
46-21	8924-8926	of	_
46-22	8927-8930	OUT	_
46-23	8931-8932	,	_
46-24	8933-8938	while	_
46-25	8939-8944	other	_
46-26	8945-8951	blocks	_
46-27	8952-8961	contained	_
46-28	8962-8966	four	_
46-29	8967-8973	blocks	_
46-30	8974-8976	of	_
46-31	8977-8979	IN	_
46-32	8980-8983	and	_
46-33	8984-8988	five	_
46-34	8989-8995	blocks	_
46-35	8996-8998	of	_
46-36	8999-9002	OUT	_
46-37	9003-9004	.	_

47-1	9005-9008	For	_
47-2	9009-9012	the	_
47-3	9013-9015	IN	_
47-4	9016-9025	condition	_
47-5	9026-9027	,	_
47-6	9028-9036	subjects	_
47-7	9037-9041	were	_
47-8	9042-9052	instructed	_
47-9	9053-9055	to	_
47-10	9056-9062	attend	_
47-11	9063-9065	to	_
47-12	9066-9072	bodily	_
47-13	9073-9083	sensations	_
47-14	9084-9094	associated	_
47-15	9095-9099	with	_
47-16	9100-9105	their	_
47-17	9106-9115	breathing	_
47-18	9116-9121	cycle	_
47-19	9122-9126	with	_
47-20	9127-9130	the	_
47-21	9131-9140	following	_
47-22	9141-9153	instructions	_
47-23	9154-9155	:	_
47-24	9156-9157	“	_
47-25	9158-9164	Please	_
47-26	9165-9168	pay	_
47-27	9169-9178	attention	_
47-28	9179-9181	to	_
47-29	9182-9185	the	_
47-30	9186-9194	physical	_
47-31	9195-9204	sensation	_
47-32	9205-9207	of	_
47-33	9208-9211	the	_
47-34	9212-9218	breath	_
47-35	9219-9227	wherever	_
47-36	9228-9231	you	_
47-37	9232-9236	feel	_
47-38	9237-9239	it	_
47-39	9240-9244	most	_
47-40	9245-9253	strongly	_
47-41	9254-9256	in	_
47-42	9257-9260	the	_
47-43	9261-9265	body	_
47-44	9266-9267	.	_

48-1	9268-9274	Follow	_
48-2	9275-9278	the	_
48-3	9279-9286	natural	_
48-4	9287-9290	and	_
48-5	9291-9302	spontaneous	_
48-6	9303-9311	movement	_
48-7	9312-9314	of	_
48-8	9315-9318	the	_
48-9	9319-9325	breath	_
48-10	9326-9327	,	_
48-11	9328-9331	not	_
48-12	9332-9338	trying	_
48-13	9339-9341	to	_
48-14	9342-9348	change	_
48-15	9349-9351	it	_
48-16	9352-9354	in	_
48-17	9355-9358	any	_
48-18	9359-9362	way	_
48-19	9363-9364	.	_

49-1	9365-9369	Just	_
49-2	9370-9373	pay	_
49-3	9374-9383	attention	_
49-4	9384-9386	to	_
49-5	9387-9389	it	_
49-6	9390-9391	.	_

50-1	9392-9394	If	_
50-2	9395-9398	you	_
50-3	9399-9403	find	_
50-4	9404-9408	that	_
50-5	9409-9413	your	_
50-6	9414-9423	attention	_
50-7	9424-9427	has	_
50-8	9428-9436	wandered	_
50-9	9437-9439	to	_
50-10	9440-9449	something	_
50-11	9450-9454	else	_
50-12	9455-9456	,	_
50-13	9457-9463	gently	_
50-14	9464-9467	but	_
50-15	9468-9474	firmly	_
50-16	9475-9480	bring	_
50-17	9481-9483	it	_
50-18	9484-9488	back	_
50-19	9489-9491	to	_
50-20	9492-9495	the	_
50-21	9496-9504	physical	_
50-22	9505-9515	sensations	_
50-23	9516-9518	of	_
50-24	9519-9522	the	_
50-25	9523-9529	breath	_
50-26	9530-9532	in	_
50-27	9533-9536	the	_
50-28	9537-9541	body	_
50-29	9542-9543	”	_
50-30	9544-9545	.	_

51-1	9546-9552	During	_
51-2	9553-9556	the	_
51-3	9557-9559	IN	_
51-4	9560-9569	condition	_
51-5	9570-9571	,	_
51-6	9572-9574	an	_
51-7	9575-9576	“	_
51-8	9577-9578	O	_
51-9	9579-9580	”	_
51-10	9581-9589	appeared	_
51-11	9590-9592	on	_
51-12	9593-9596	the	_
51-13	9597-9603	center	_
51-14	9604-9606	of	_
51-15	9607-9610	the	_
51-16	9611-9617	screen	_
51-17	9618-9621	for	_
51-18	9622-9624	36	_
51-19	9625-9626	s	_
51-20	9627-9628	,	_
51-21	9629-9631	on	_
51-22	9632-9637	which	_
51-23	9638-9646	subjects	_
51-24	9647-9651	were	_
51-25	9652-9662	instructed	_
51-26	9663-9665	to	_
51-27	9666-9669	fix	_
51-28	9670-9675	their	_
51-29	9676-9680	gaze	_
51-30	9681-9686	while	_
51-31	9687-9701	simultaneously	_
51-32	9702-9711	attending	_
51-33	9712-9714	to	_
51-34	9715-9718	the	_
51-35	9719-9729	sensations	_
51-36	9730-9732	of	_
51-37	9733-9738	their	_
51-38	9739-9748	breathing	_
51-39	9749-9754	cycle	_
51-40	9755-9756	.	_

52-1	9757-9760	The	_
52-2	9761-9764	OUT	http://maven.renci.org/NeuroBridge/neurobridge#PhysiologicalState
52-3	9765-9774	condition	http://maven.renci.org/NeuroBridge/neurobridge#PhysiologicalState
52-4	9775-9784	consisted	_
52-5	9785-9787	of	_
52-6	9788-9789	a	_
52-7	9790-9791	“	_
52-8	9792-9798	1-back	_
52-9	9799-9800	”	_
52-10	9801-9805	task	_
52-11	9806-9807	,	_
52-12	9808-9813	which	_
52-13	9814-9816	we	_
52-14	9817-9827	considered	_
52-15	9828-9830	to	_
52-16	9831-9833	be	_
52-17	9834-9836	an	_
52-18	9837-9846	attention	_
52-19	9847-9854	control	_
52-20	9855-9864	condition	_
52-21	9865-9866	.	_

53-1	9867-9873	During	_
53-2	9874-9877	the	_
53-3	9878-9881	OUT	_
53-4	9882-9888	blocks	_
53-5	9889-9890	,	_
53-6	9891-9892	a	_
53-7	9893-9899	letter	_
53-8	9900-9904	from	_
53-9	9905-9908	the	_
53-10	9909-9912	set	_
53-11	9913-9914	(	_
53-12	9915-9916	A	_
53-13	9917-9918	,	_
53-14	9919-9920	B	_
53-15	9921-9922	,	_
53-16	9923-9924	C	_
53-17	9925-9926	,	_
53-18	9927-9928	D	_
53-19	9929-9930	)	_
53-20	9931-9934	was	_
53-21	9935-9944	presented	_
53-22	9945-9948	for	_
53-23	9949-9952	500	_
53-24	9953-9955	ms	_
53-25	9956-9958	in	_
53-26	9959-9960	a	_
53-27	9961-9973	pseudorandom	_
53-28	9974-9982	sequence	_
53-29	9983-9984	.	_

54-1	9985-9986	A	_
54-2	9987-9995	fixation	_
54-3	9996-10001	cross	_
54-4	10002-10005	was	_
54-5	10006-10015	presented	_
54-6	10016-10018	in	_
54-7	10019-10026	between	_
54-8	10027-10031	each	_
54-9	10032-10038	letter	_
54-10	10039-10042	for	_
54-11	10043-10046	900	_
54-12	10047-10049	ms	_
54-13	10050-10051	.	_

55-1	10052-10056	When	_
55-2	10057-10058	a	_
55-3	10059-10065	letter	_
55-4	10066-10074	repeated	_
55-5	10075-10076	,	_
55-6	10077-10080	the	_
55-7	10081-10092	participant	_
55-8	10093-10096	was	_
55-9	10097-10107	instructed	_
55-10	10108-10110	to	_
55-11	10111-10116	press	_
55-12	10117-10118	a	_
55-13	10119-10122	key	_
55-14	10123-10125	on	_
55-15	10126-10129	the	_
55-16	10130-10136	button	_
55-17	10137-10140	box	_
55-18	10141-10142	.	_

56-1	10143-10146	The	_
56-2	10147-10150	OUT	_
56-3	10151-10157	blocks	_
56-4	10158-10164	lasted	_
56-5	10165-10169	38.7	_
56-6	10170-10172	s.	_
56-7	10173-10176	The	_
56-8	10177-10185	sequence	_
56-9	10186-10188	of	_
56-10	10189-10196	letters	_
56-11	10197-10206	presented	_
56-12	10207-10208	,	_
56-13	10209-10212	key	_
56-14	10213-10220	presses	_
56-15	10221-10222	,	_
56-16	10223-10226	and	_
56-17	10227-10235	response	_
56-18	10236-10241	times	_
56-19	10242-10246	were	_
56-20	10247-10255	recorded	_
56-21	10256-10259	for	_
56-22	10260-10264	each	_
56-23	10265-10268	OUT	_
56-24	10269-10274	block	_
56-25	10275-10276	.	_

57-1	10277-10282	Prior	_
57-2	10283-10285	to	_
57-3	10286-10290	each	_
57-4	10291-10296	block	_
57-5	10297-10298	,	_
57-6	10299-10302	the	_
57-7	10303-10310	subject	_
57-8	10311-10314	was	_
57-9	10315-10324	presented	_
57-10	10325-10329	with	_
57-11	10330-10332	an	_
57-12	10333-10344	instruction	_
57-13	10345-10351	screen	_
57-14	10352-10355	for	_
57-15	10356-10358	10	_
57-16	10359-10360	s	_
57-17	10361-10365	that	_
57-18	10366-10370	cued	_
57-19	10371-10375	them	_
57-20	10376-10378	to	_
57-21	10379-10382	the	_
57-22	10383-10391	upcoming	_
57-23	10392-10397	block	_
57-24	10398-10399	.	_

58-1	10400-10404	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
58-2	10405-10416	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
58-3	10417-10420	and	_
58-4	10421-10429	analysis	_
58-5	10430-10437	Imaging	_
58-6	10438-10444	set-up	_
58-7	10445-10451	Images	_
58-8	10452-10456	were	_
58-9	10457-10465	acquired	_
58-10	10466-10470	with	_
58-11	10471-10472	a	_
58-12	10473-10474	3	_
58-13	10475-10476	T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
58-14	10477-10484	Siemens	_
58-15	10485-10493	MAGNETON	_
58-16	10494-10500	Prisma	http://maven.renci.org/NeuroBridge/neurobridge#Hypopituitarism
58-17	10501-10507	System	_
58-18	10508-10509	,	_
58-19	10510-10514	with	_
58-20	10515-10516	a	_
58-21	10517-10527	20-channel	_
58-22	10528-10532	head	_
58-23	10533-10537	coil	_
58-24	10538-10539	.	_

59-1	10540-10550	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
59-2	10551-10557	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
59-3	10558-10562	were	_
59-4	10563-10571	obtained	_
59-5	10572-10577	using	_
59-6	10578-10579	a	_
59-7	10580-10588	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
59-8	10589-10593	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
59-9	10594-10595	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
59-10	10596-10607	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
59-11	10608-10609	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
59-12	10610-10612	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
59-13	10613-10614	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
59-14	10615-10624	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
59-15	10625-10630	pulse	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
59-16	10631-10639	sequence	_
59-17	10640-10641	(	_
59-18	10642-10644	TR	_
59-19	10645-10646	=	_
59-20	10647-10651	2000	_
59-21	10652-10654	ms	_
59-22	10655-10656	,	_
59-23	10657-10660	one	_
59-24	10661-10665	shot	_
59-25	10666-10669	per	_
59-26	10670-10680	repetition	_
59-27	10681-10682	,	_
59-28	10683-10685	TE	_
59-29	10686-10687	=	_
59-30	10688-10690	25	_
59-31	10691-10693	ms	_
59-32	10694-10695	,	_
59-33	10696-10700	flip	_
59-34	10701-10706	angle	_
59-35	10707-10708	=	_
59-36	10709-10712	90°	_
59-37	10713-10714	,	_
59-38	10715-10717	64	_
59-39	10718-10719	×	_
59-40	10720-10722	64	_
59-41	10723-10731	in-plane	_
59-42	10732-10742	resolution	_
59-43	10743-10744	)	_
59-44	10745-10746	.	_

60-1	10747-10756	Forty-one	_
60-2	10757-10763	slices	_
60-3	10764-10772	covering	_
60-4	10773-10776	the	_
60-5	10777-10783	entire	_
60-6	10784-10789	brain	_
60-7	10790-10794	were	_
60-8	10795-10803	acquired	_
60-9	10804-10808	with	_
60-10	10809-10810	a	_
60-11	10811-10816	voxel	_
60-12	10817-10827	resolution	_
60-13	10828-10830	of	_
60-14	10831-10832	3	_
60-15	10833-10838	cubic	_
60-16	10839-10841	mm	_
60-17	10842-10843	.	_

61-1	10844-10854	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
61-2	10855-10866	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
61-3	10867-10889	magnetization-prepared	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
61-4	10890-10895	rapid	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
61-5	10896-10904	gradient	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
61-6	10905-10909	echo	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
61-7	10910-10911	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
61-8	10912-10918	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
61-9	10919-10920	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
61-10	10921-10927	images	_
61-11	10928-10932	were	_
61-12	10933-10941	acquired	_
61-13	10942-10946	with	_
61-14	10947-10950	the	_
61-15	10951-10960	following	_
61-16	10961-10971	parameters	_
61-17	10972-10973	:	_
61-18	10974-10976	TR	_
61-19	10977-10978	=	_
61-20	10979-10983	1950	_
61-21	10984-10986	ms	_
61-22	10987-10988	,	_
61-23	10989-10991	TE	_
61-24	10992-10993	=	_
61-25	10994-10998	2.26	_
61-26	10999-11001	ms	_
61-27	11002-11003	,	_
61-28	11004-11006	TI	_
61-29	11007-11008	=	_
61-30	11009-11012	900	_
61-31	11013-11015	ms	_
61-32	11016-11017	,	_
61-33	11018-11022	Flip	_
61-34	11023-11028	Angle	_
61-35	11029-11030	=	_
61-36	11031-11033	7°	_
61-37	11034-11035	,	_
61-38	11036-11042	matrix	_
61-39	11043-11044	=	_
61-40	11045-11048	256	_
61-41	11049-11050	×	_
61-42	11051-11054	224	_
61-43	11055-11056	,	_
61-44	11057-11058	1	_
61-45	11059-11061	mm	_
61-46	11062-11071	isotropic	_
61-47	11072-11082	resolution	_
61-48	11083-11084	,	_
61-49	11085-11088	176	_
61-50	11089-11097	sagittal	_
61-51	11098-11104	slices	_
61-52	11105-11106	,	_
61-53	11107-11118	acquisition	_
61-54	11119-11123	time	_
61-55	11124-11125	=	_
61-56	11126-11129	241	_
61-57	11130-11132	s.	_
61-58	11133-11144	Respiration	_
61-59	11145-11148	and	_
61-60	11149-11154	pulse	_
61-61	11155-11163	oximetry	_
61-62	11164-11168	were	_
61-63	11169-11177	measured	_
61-64	11178-11184	during	_
61-65	11185-11193	scanning	_
61-66	11194-11199	using	_
61-67	11200-11206	Biopac	_
61-68	11207-11212	MP150	_
61-69	11213-11221	hardware	_
61-70	11222-11225	and	_
61-71	11226-11239	MR-compatible	_
61-72	11240-11251	respiratory	_
61-73	11252-11259	stretch	_
61-74	11260-11270	transducer	_
61-75	11271-11274	and	_
61-76	11275-11280	pulse	_
61-77	11281-11289	oximeter	_
61-78	11290-11291	(	_
61-79	11292-11297	Nonin	_
61-80	11298-11305	Medical	_
61-81	11306-11307	,	_
61-82	11308-11314	8600FO	_
61-83	11315-11316	)	_
61-84	11317-11318	.	_

62-1	11319-11332	Physiological	_
62-2	11333-11337	data	_
62-3	11338-11342	were	_
62-4	11343-11350	sampled	_
62-5	11351-11355	with	_
62-6	11356-11357	a	_
62-7	11358-11362	1000	_
62-8	11363-11365	Hz	_
62-9	11366-11374	sampling	_
62-10	11375-11379	rate	_
62-11	11380-11381	.	_

63-1	11382-11385	The	_
63-2	11386-11397	acquisition	_
63-3	11398-11401	was	_
63-4	11402-11414	synchronized	_
63-5	11415-11417	to	_
63-6	11418-11421	the	_
63-7	11422-11429	scanner	_
63-8	11430-11433	via	_
63-9	11434-11435	a	_
63-10	11436-11439	TTL	_
63-11	11440-11445	pulse	_
63-12	11446-11447	,	_
63-13	11448-11451	and	_
63-14	11452-11460	recorded	_
63-15	11461-11463	in	_
63-16	11464-11470	Biopac	_
63-17	11471-11483	Acqknowledge	_
63-18	11484-11492	software	_
63-19	11493-11494	.	_

64-1	11495-11498	The	_
64-2	11499-11505	IN-OUT	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
64-3	11506-11515	Attention	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
64-4	11516-11520	task	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder
64-5	11521-11524	was	_
64-6	11525-11533	scripted	_
64-7	11534-11539	using	_
64-8	11540-11546	MATLAB	_
64-9	11547-11550	and	_
64-10	11551-11563	Psychtoolbox	_
64-11	11564-11566	3.	_
64-12	11567-11571	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
64-13	11572-11586	pre-processing	_
64-14	11587-11596	RETROICOR	_
64-15	11597-11600	and	_
64-16	11601-11612	respiratory	_
64-17	11613-11616	and	_
64-18	11617-11624	cardiac	_
64-19	11625-11633	response	_
64-20	11634-11643	functions	_
64-21	11644-11645	(	_
64-22	11646-11653	RVHRCOR	_
64-23	11654-11655	)	_
64-24	11656-11660	were	_
64-25	11661-11668	applied	_
64-26	11669-11671	to	_
64-27	11672-11675	the	_
64-28	11676-11686	functional	_
64-29	11687-11694	volumes	_
64-30	11695-11697	to	_
64-31	11698-11704	reduce	_
64-32	11705-11717	non-neuronal	_
64-33	11718-11731	contributions	_
64-34	11732-11734	of	_
64-35	11735-11748	physiological	_
64-36	11749-11754	noise	_
64-37	11755-11756	.	_

65-1	11757-11766	RETROICOR	_
65-2	11767-11773	models	_
65-3	11774-11782	periodic	_
65-4	11783-11792	pulsatile	_
65-5	11793-11798	noise	_
65-6	11799-11801	in	_
65-7	11802-11805	the	_
65-8	11806-11810	BOLD	_
65-9	11811-11815	time	_
65-10	11816-11822	series	_
65-11	11823-11833	associated	_
65-12	11834-11838	with	_
65-13	11839-11850	respiratory	_
65-14	11851-11854	and	_
65-15	11855-11862	cardiac	_
65-16	11863-11869	cycles	_
65-17	11870-11872	as	_
65-18	11873-11874	a	_
65-19	11875-11884	low-order	_
65-20	11885-11892	Fourier	_
65-21	11893-11898	phase	_
65-22	11899-11908	expansion	_
65-23	11909-11910	.	_

66-1	11911-11918	RVHRCOR	_
66-2	11919-11926	removes	_
66-3	11927-11940	low-frequency	_
66-4	11941-11948	cardiac	_
66-5	11949-11952	and	_
66-6	11953-11964	respiratory	_
66-7	11965-11972	effects	_
66-8	11973-11975	by	_
66-9	11976-11986	convolving	_
66-10	11987-11990	the	_
66-11	11991-12002	respiratory	_
66-12	12003-12006	and	_
66-13	12007-12014	cardiac	_
66-14	12015-12019	data	_
66-15	12020-12024	with	_
66-16	12025-12030	their	_
66-17	12031-12041	respective	_
66-18	12042-12050	response	_
66-19	12051-12060	functions	_
66-20	12061-12062	.	_

67-1	12063-12066	The	_
67-2	12067-12076	convolved	_
67-3	12077-12084	cardiac	_
67-4	12085-12088	and	_
67-5	12089-12100	respiratory	_
67-6	12101-12110	waveforms	_
67-7	12111-12114	are	_
67-8	12115-12119	then	_
67-9	12120-12124	used	_
67-10	12125-12127	as	_
67-11	12128-12138	regressors	_
67-12	12139-12142	for	_
67-13	12143-12147	each	_
67-14	12148-12153	voxel	_
67-15	12154-12156	's	_
67-16	12157-12161	time	_
67-17	12162-12168	series	_
67-18	12169-12174	using	_
67-19	12175-12180	least	_
67-20	12181-12188	squares	_
67-21	12189-12190	.	_

68-1	12191-12200	RETROICOR	_
68-2	12201-12202	(	_
68-3	12203-12208	order	_
68-4	12209-12210	=	_
68-5	12211-12212	4	_
68-6	12213-12214	)	_
68-7	12215-12218	and	_
68-8	12219-12226	RVHRCOR	_
68-9	12227-12231	were	_
68-10	12232-12241	performed	_
68-11	12242-12244	in	_
68-12	12245-12251	MATLAB	_
68-13	12252-12257	using	_
68-14	12258-12262	code	_
68-15	12263-12271	obtained	_
68-16	12272-12276	from	_
68-17	12277-12279	C.	_
68-18	12280-12285	Chang	_
68-19	12286-12287	.	_

69-1	12288-12298	Subsequent	_
69-2	12299-12313	pre-processing	_
69-3	12314-12319	steps	_
69-4	12320-12324	were	_
69-5	12325-12332	carried	_
69-6	12333-12336	out	_
69-7	12337-12339	in	_
69-8	12340-12343	FSL	_
69-9	12344-12345	(	_
69-10	12346-12351	FMRIB	_
69-11	12352-12354	's	_
69-12	12355-12363	Software	_
69-13	12364-12371	Library	_
69-14	12372-12373	;	_
69-15	12374-12378	http	_
69-16	12379-12380	:	_
69-17	12381-12414	//fsl.fmrib.ox.ac.uk/fsl/fslwiki/	_
69-18	12415-12416	)	_
69-19	12417-12420	and	_
69-20	12421-12429	included	_
69-21	12430-12435	skull	_
69-22	12436-12445	stripping	_
69-23	12446-12450	with	_
69-24	12451-12454	BET	_
69-25	12455-12456	,	_
69-26	12457-12463	motion	_
69-27	12464-12474	correction	_
69-28	12475-12476	(	_
69-29	12477-12484	MCFLIRT	_
69-30	12485-12486	)	_
69-31	12487-12488	,	_
69-32	12489-12501	slice-timing	_
69-33	12502-12512	correction	_
69-34	12513-12514	,	_
69-35	12515-12524	high-pass	_
69-36	12525-12533	temporal	_
69-37	12534-12543	filtering	_
69-38	12544-12545	(	_
69-39	12546-12548	90	_
69-40	12549-12550	s	_
69-41	12551-12552	)	_
69-42	12553-12554	,	_
69-43	12555-12558	and	_
69-44	12559-12566	spatial	_
69-45	12567-12576	smoothing	_
69-46	12577-12582	using	_
69-47	12583-12584	a	_
69-48	12585-12586	5	_
69-49	12587-12589	mm	_
69-50	12590-12598	Gaussian	_
69-51	12599-12603	FWHM	_
69-52	12604-12610	filter	_
69-53	12611-12612	.	_

70-1	12613-12623	Additional	_
70-2	12624-12631	sources	_
70-3	12632-12634	of	_
70-4	12635-12643	movement	_
70-5	12644-12647	and	_
70-6	12648-12655	scanner	_
70-7	12656-12661	noise	_
70-8	12662-12666	were	_
70-9	12667-12674	removed	_
70-10	12675-12680	using	_
70-11	12681-12684	FSL	_
70-12	12685-12687	's	_
70-13	12688-12695	MELODIC	_
70-14	12696-12699	ICA	_
70-15	12700-12703	for	_
70-16	12704-12708	each	_
70-17	12709-12719	individual	_
70-18	12720-12723	run	_
70-19	12724-12725	.	_

71-1	12726-12739	Subject-level	_
71-2	12740-12749	ICA-based	_
71-3	12750-12759	denoising	_
71-4	12760-12773	substantially	_
71-5	12774-12782	improves	_
71-6	12783-12786	the	_
71-7	12787-12802	reproducibility	_
71-8	12803-12805	of	_
71-9	12806-12815	group-ICA	_
71-10	12816-12830	decompositions	_
71-11	12831-12839	relative	_
71-12	12840-12842	to	_
71-13	12843-12847	both	_
71-14	12848-12854	motion	_
71-15	12855-12864	scrubbing	_
71-16	12865-12868	and	_
71-17	12869-12877	nuisance	_
71-18	12878-12888	regression	_
71-19	12889-12890	.	_

72-1	12891-12895	Each	_
72-2	12896-12905	component	_
72-3	12906-12909	for	_
72-4	12910-12914	each	_
72-5	12915-12922	subject	_
72-6	12923-12926	and	_
72-7	12927-12930	run	_
72-8	12931-12934	was	_
72-9	12935-12943	manually	_
72-10	12944-12953	inspected	_
72-11	12954-12957	and	_
72-12	12958-12965	labeled	_
72-13	12966-12968	by	_
72-14	12969-12971	an	_
72-15	12972-12984	experimenter	_
72-16	12985-12990	blind	_
72-17	12991-12993	to	_
72-18	12994-13005	participant	_
72-19	13006-13015	diagnoses	_
72-20	13016-13017	.	_

73-1	13018-13028	Components	_
73-2	13029-13036	flagged	_
73-3	13037-13039	as	_
73-4	13040-13048	artifact	_
73-5	13049-13053	were	_
73-6	13054-13063	regressed	_
73-7	13064-13068	from	_
73-8	13069-13072	the	_
73-9	13073-13083	functional	_
73-10	13084-13090	volume	_
73-11	13091-13092	.	_

74-1	13093-13096	The	_
74-2	13097-13107	functional	_
74-3	13108-13115	volumes	_
74-4	13116-13120	were	_
74-5	13121-13130	realigned	_
74-6	13131-13133	to	_
74-7	13134-13138	each	_
74-8	13139-13150	participant	_
74-9	13151-13153	's	_
74-10	13154-13164	respective	_
74-11	13165-13176	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
74-12	13177-13187	anatomical	_
74-13	13188-13193	image	_
74-14	13194-13195	,	_
74-15	13196-13200	then	_
74-16	13201-13211	normalized	_
74-17	13212-13216	into	_
74-18	13217-13225	standard	_
74-19	13226-13231	space	_
74-20	13232-13237	using	_
74-21	13238-13252	12°-of-freedom	_
74-22	13253-13259	affine	_
74-23	13260-13274	transformation	_
74-24	13275-13278	and	_
74-25	13279-13280	2	_
74-26	13281-13283	mm	_
74-27	13284-13294	resolution	_
74-28	13295-13296	.	_

75-1	13297-13302	Group	_
75-2	13303-13314	independent	_
75-3	13315-13325	components	_
75-4	13326-13334	analysis	_
75-5	13335-13337	To	_
75-6	13338-13346	identify	_
75-7	13347-13358	group-level	_
75-8	13359-13368	intrinsic	_
75-9	13369-13379	functional	_
75-10	13380-13388	networks	_
75-11	13389-13390	,	_
75-12	13391-13393	we	_
75-13	13394-13402	utilized	_
75-14	13403-13406	the	_
75-15	13407-13419	Multivariate	_
75-16	13420-13431	Exploratory	_
75-17	13432-13438	Linear	_
75-18	13439-13448	Optimized	_
75-19	13449-13462	Decomposition	_
75-20	13463-13467	into	_
75-21	13468-13479	Independent	_
75-22	13480-13490	Components	_
75-23	13491-13492	(	_
75-24	13493-13500	MELODIC	_
75-25	13501-13502	)	_
75-26	13503-13512	algorithm	_
75-27	13513-13515	in	_
75-28	13516-13519	FSL	_
75-29	13520-13521	.	_

76-1	13522-13533	Independent	_
76-2	13534-13544	components	_
76-3	13545-13553	analysis	_
76-4	13554-13563	separates	_
76-5	13564-13574	underlying	_
76-6	13575-13582	sources	_
76-7	13583-13587	from	_
76-8	13588-13589	a	_
76-9	13590-13598	linearly	_
76-10	13599-13604	mixed	_
76-11	13605-13617	multivariate	_
76-12	13618-13624	signal	_
76-13	13625-13626	.	_

77-1	13627-13639	Preprocessed	_
77-2	13640-13644	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
77-3	13645-13649	data	_
77-4	13650-13654	from	_
77-5	13655-13659	each	_
77-6	13660-13667	subject	_
77-7	13668-13671	and	_
77-8	13672-13675	run	_
77-9	13676-13680	were	_
77-10	13681-13691	temporally	_
77-11	13692-13704	concatenated	_
77-12	13705-13709	into	_
77-13	13710-13711	a	_
77-14	13712-13718	single	_
77-15	13719-13721	4D	_
77-16	13722-13726	file	_
77-17	13727-13728	(	_
77-18	13729-13733	each	_
77-19	13734-13741	subject	_
77-20	13742-13750	provided	_
77-21	13751-13754	two	_
77-22	13755-13759	runs	_
77-23	13760-13762	of	_
77-24	13763-13767	data	_
77-25	13768-13769	,	_
77-26	13770-13774	less	_
77-27	13775-13778	the	_
77-28	13779-13783	four	_
77-29	13784-13792	subjects	_
77-30	13793-13796	who	_
77-31	13797-13805	provided	_
77-32	13806-13810	only	_
77-33	13811-13814	one	_
77-34	13815-13818	run	_
77-35	13819-13820	,	_
77-36	13821-13824	for	_
77-37	13825-13826	a	_
77-38	13827-13832	total	_
77-39	13833-13835	of	_
77-40	13836-13838	82	_
77-41	13839-13843	runs	_
77-42	13844-13845	)	_
77-43	13846-13849	and	_
77-44	13850-13859	submitted	_
77-45	13860-13862	to	_
77-46	13863-13870	MELODIC	_
77-47	13871-13879	analysis	_
77-48	13880-13881	,	_
77-49	13882-13886	with	_
77-50	13887-13895	variance	_
77-51	13896-13909	normalization	_
77-52	13910-13911	.	_

78-1	13912-13916	Thus	_
78-2	13917-13918	,	_
78-3	13919-13922	the	_
78-4	13923-13928	group	_
78-5	13929-13932	ICA	_
78-6	13933-13941	solution	_
78-7	13942-13950	reflects	_
78-8	13951-13954	the	_
78-9	13955-13963	combined	_
78-10	13964-13977	contributions	_
78-11	13978-13980	of	_
78-12	13981-13985	both	_
78-13	13986-13989	the	_
78-14	13990-13994	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
78-15	13995-13998	and	_
78-16	13999-14005	noPTSD	_
78-17	14006-14012	groups	_
78-18	14013-14014	.	_

79-1	14015-14018	The	_
79-2	14019-14033	dimensionality	_
79-3	14034-14036	of	_
79-4	14037-14040	the	_
79-5	14041-14049	solution	_
79-6	14050-14053	was	_
79-7	14054-14065	constrained	_
79-8	14066-14068	to	_
79-9	14069-14071	20	_
79-10	14072-14080	networks	_
79-11	14081-14082	,	_
79-12	14083-14084	a	_
79-13	14085-14090	level	_
79-14	14091-14093	of	_
79-15	14094-14105	granularity	_
79-16	14106-14114	commonly	_
79-17	14115-14119	used	_
79-18	14120-14122	to	_
79-19	14123-14131	identify	_
79-20	14132-14143	large-scale	_
79-21	14144-14152	networks	_
79-22	14153-14154	.	_

80-1	14155-14165	Thereafter	_
80-2	14166-14167	,	_
80-3	14168-14171	the	_
80-4	14172-14174	20	_
80-5	14175-14186	group-level	_
80-6	14187-14197	normalized	_
80-7	14198-14206	networks	_
80-8	14207-14211	were	_
80-9	14212-14221	spatially	_
80-10	14222-14238	cross-correlated	_
80-11	14239-14246	against	_
80-12	14247-14249	20	_
80-13	14250-14257	network	_
80-14	14258-14266	solution	_
80-15	14267-14269	to	_
80-16	14270-14279	determine	_
80-17	14280-14285	their	_
80-18	14286-14300	correspondence	_
80-19	14301-14303	to	_
80-20	14304-14305	a	_
80-21	14306-14315	canonical	_
80-22	14316-14319	set	_
80-23	14320-14322	of	_
80-24	14323-14332	intrinsic	_
80-25	14333-14341	networks	_
80-26	14342-14345	and	_
80-27	14346-14355	artifacts	_
80-28	14356-14357	.	_

81-1	14358-14362	Dual	_
81-2	14363-14373	regression	_
81-3	14374-14376	to	_
81-4	14377-14383	obtain	_
81-5	14384-14397	subject-level	_
81-6	14398-14406	networks	_
81-7	14407-14409	In	_
81-8	14410-14413	the	_
81-9	14414-14419	first	_
81-10	14420-14425	stage	_
81-11	14426-14428	of	_
81-12	14429-14432	the	_
81-13	14433-14437	dual	_
81-14	14438-14448	regression	_
81-15	14449-14450	,	_
81-16	14451-14454	the	_
81-17	14455-14468	unthresholded	_
81-18	14469-14480	group-level	_
81-19	14481-14489	networks	_
81-20	14490-14493	are	_
81-21	14494-14499	first	_
81-22	14500-14509	regressed	_
81-23	14510-14514	onto	_
81-24	14515-14519	each	_
81-25	14520-14531	participant	_
81-26	14532-14534	's	_
81-27	14535-14539	fMRI	_
81-28	14540-14546	series	_
81-29	14547-14549	to	_
81-30	14550-14557	extract	_
81-31	14558-14570	beta-weights	_
81-32	14571-14575	that	_
81-33	14576-14580	form	_
81-34	14581-14582	a	_
81-35	14583-14599	subject-specific	_
81-36	14600-14604	time	_
81-37	14605-14611	series	_
81-38	14612-14615	for	_
81-39	14616-14620	each	_
81-40	14621-14630	component	_
81-41	14631-14634	and	_
81-42	14635-14645	functional	_
81-43	14646-14649	run	_
81-44	14650-14651	(	_
81-45	14652-14655	the	_
81-46	14656-14663	spatial	_
81-47	14664-14674	regression	_
81-48	14675-14676	)	_
81-49	14677-14678	.	_

82-1	14679-14683	Next	_
82-2	14684-14685	,	_
82-3	14686-14689	the	_
82-4	14690-14709	variance-normalized	_
82-5	14710-14714	time	_
82-6	14715-14721	series	_
82-7	14722-14725	for	_
82-8	14726-14730	each	_
82-9	14731-14740	component	_
82-10	14741-14744	and	_
82-11	14745-14748	run	_
82-12	14749-14757	obtained	_
82-13	14758-14762	from	_
82-14	14763-14766	the	_
82-15	14767-14772	first	_
82-16	14773-14778	stage	_
82-17	14779-14782	are	_
82-18	14783-14787	used	_
82-19	14788-14790	as	_
82-20	14791-14800	predictor	_
82-21	14801-14808	vectors	_
82-22	14809-14812	for	_
82-23	14813-14817	each	_
82-24	14818-14829	participant	_
82-25	14830-14832	's	_
82-26	14833-14837	fMRI	_
82-27	14838-14844	series	_
82-28	14845-14847	to	_
82-29	14848-14854	obtain	_
82-30	14855-14856	a	_
82-31	14857-14873	subject-specific	_
82-32	14874-14883	component	_
82-33	14884-14887	map	_
82-34	14888-14889	(	_
82-35	14890-14893	the	_
82-36	14894-14902	temporal	_
82-37	14903-14913	regression	_
82-38	14914-14915	)	_
82-39	14916-14917	.	_

83-1	14918-14923	These	_
83-2	14924-14935	whole-brain	_
83-3	14936-14943	spatial	_
83-4	14944-14948	maps	_
83-5	14949-14956	reflect	_
83-6	14957-14961	each	_
83-7	14962-14967	voxel	_
83-8	14968-14970	's	_
83-9	14971-14982	correlation	_
83-10	14983-14987	with	_
83-11	14988-14991	the	_
83-12	14992-15003	group-level	_
83-13	15004-15011	network	_
83-14	15012-15013	;	_
83-15	15014-15026	consequently	_
83-16	15027-15028	,	_
83-17	15029-15039	functional	_
83-18	15040-15052	connectivity	_
83-19	15053-15055	of	_
83-20	15056-15057	a	_
83-21	15058-15063	given	_
83-22	15064-15071	network	_
83-23	15072-15075	can	_
83-24	15076-15084	manifest	_
83-25	15085-15087	in	_
83-26	15088-15091	any	_
83-27	15092-15098	region	_
83-28	15099-15101	of	_
83-29	15102-15105	the	_
83-30	15106-15111	brain	_
83-31	15112-15113	,	_
83-32	15114-15124	regardless	_
83-33	15125-15127	of	_
83-34	15128-15135	whether	_
83-35	15136-15140	that	_
83-36	15141-15147	region	_
83-37	15148-15150	is	_
83-38	15151-15160	typically	_
83-39	15161-15171	associated	_
83-40	15172-15176	with	_
83-41	15177-15180	the	_
83-42	15181-15190	canonical	_
83-43	15191-15198	network	_
83-44	15199-15200	.	_

84-1	15201-15205	This	_
84-2	15206-15214	approach	_
84-3	15215-15221	allows	_
84-4	15222-15236	identification	_
84-5	15237-15239	of	_
84-6	15240-15245	group	_
84-7	15246-15257	differences	_
84-8	15258-15260	in	_
84-9	15261-15268	spatial	_
84-10	15269-15281	connectivity	_
84-11	15282-15284	of	_
84-12	15285-15295	functional	_
84-13	15296-15304	networks	_
84-14	15305-15306	.	_

85-1	15307-15309	We	_
85-2	15310-15317	carried	_
85-3	15318-15321	out	_
85-4	15322-15326	dual	_
85-5	15327-15337	regression	_
85-6	15338-15340	on	_
85-7	15341-15345	each	_
85-8	15346-15357	group-level	_
85-9	15358-15365	network	_
85-10	15366-15378	individually	_
85-11	15379-15380	,	_
85-12	15381-15390	excluding	_
85-13	15391-15392	:	_
85-14	15393-15394	1	_
85-15	15395-15396	)	_
85-16	15397-15400	the	_
85-17	15401-15404	six	_
85-18	15405-15413	networks	_
85-19	15414-15420	deemed	_
85-20	15421-15432	artifactual	_
85-21	15433-15438	based	_
85-22	15439-15441	on	_
85-23	15442-15448	visual	_
85-24	15449-15459	inspection	_
85-25	15460-15463	and	_
85-26	15464-15474	comparison	_
85-27	15475-15479	with	_
85-28	15480-15489	canonical	_
85-29	15490-15498	networks	_
85-30	15499-15502	and	_
85-31	15503-15504	2	_
85-32	15505-15506	)	_
85-33	15507-15510	the	_
85-34	15511-15514	six	_
85-35	15515-15523	networks	_
85-36	15524-15528	that	_
85-37	15529-15533	were	_
85-38	15534-15537	not	_
85-39	15538-15543	found	_
85-40	15544-15546	to	_
85-41	15547-15549	be	_
85-42	15550-15563	significantly	_
85-43	15564-15576	task-related	_
85-44	15577-15578	(	_
85-45	15579-15582	see	_
85-46	15583-15590	Section	_
85-47	15591-15594	3.6	_
85-48	15595-15600	below	_
85-49	15601-15602	)	_
85-50	15603-15604	.	_

86-1	15605-15609	Thus	_
86-2	15610-15611	,	_
86-3	15612-15614	we	_
86-4	15615-15622	carried	_
86-5	15623-15626	out	_
86-6	15627-15632	eight	_
86-7	15633-15641	separate	_
86-8	15642-15646	dual	_
86-9	15647-15658	regressions	_
86-10	15659-15661	on	_
86-11	15662-15665	the	_
86-12	15666-15674	networks	_
86-13	15675-15685	identified	_
86-14	15686-15688	as	_
86-15	15689-15702	significantly	_
86-16	15703-15713	associated	_
86-17	15714-15718	with	_
86-18	15719-15721	IN	_
86-19	15722-15725	and	_
86-20	15726-15729	OUT	_
86-21	15730-15740	conditions	_
86-22	15741-15743	of	_
86-23	15744-15747	the	_
86-24	15748-15752	task	_
86-25	15753-15754	.	_

87-1	15755-15759	Each	_
87-2	15760-15764	dual	_
87-3	15765-15775	regression	_
87-4	15776-15784	produced	_
87-5	15785-15788	two	_
87-6	15789-15796	spatial	_
87-7	15797-15801	maps	_
87-8	15802-15805	per	_
87-9	15806-15813	subject	_
87-10	15814-15815	(	_
87-11	15816-15829	corresponding	_
87-12	15830-15832	to	_
87-13	15833-15836	the	_
87-14	15837-15840	two	_
87-15	15841-15845	runs	_
87-16	15846-15847	,	_
87-17	15848-15852	less	_
87-18	15853-15856	the	_
87-19	15857-15861	four	_
87-20	15862-15872	exceptions	_
87-21	15873-15876	who	_
87-22	15877-15888	contributed	_
87-23	15889-15892	one	_
87-24	15893-15896	run	_
87-25	15897-15899	of	_
87-26	15900-15904	data	_
87-27	15905-15906	)	_
87-28	15907-15908	.	_

88-1	15909-15913	Each	_
88-2	15914-15921	subject	_
88-3	15922-15924	's	_
88-4	15925-15938	Z-transformed	_
88-5	15939-15943	maps	_
88-6	15944-15948	were	_
88-7	15949-15953	then	_
88-8	15954-15962	averaged	_
88-9	15963-15968	using	_
88-10	15969-15972	the	_
88-11	15973-15981	fslmaths	_
88-12	15982-15984	to	_
88-13	15985-15989	form	_
88-14	15990-15991	a	_
88-15	15992-15998	single	_
88-16	15999-16001	3D	_
88-17	16002-16006	file	_
88-18	16007-16010	for	_
88-19	16011-16015	each	_
88-20	16016-16025	component	_
88-21	16026-16027	.	_

89-1	16028-16033	These	_
89-2	16034-16042	averaged	_
89-3	16043-16059	subject-specific	_
89-4	16060-16067	spatial	_
89-5	16068-16072	maps	_
89-6	16073-16076	for	_
89-7	16077-16078	a	_
89-8	16079-16084	given	_
89-9	16085-16094	component	_
89-10	16095-16099	were	_
89-11	16100-16104	then	_
89-12	16105-16117	concatenated	_
89-13	16118-16120	to	_
89-14	16121-16125	form	_
89-15	16126-16127	a	_
89-16	16128-16130	4D	_
89-17	16131-16135	file	_
89-18	16136-16137	,	_
89-19	16138-16143	which	_
89-20	16144-16150	served	_
89-21	16151-16153	as	_
89-22	16154-16157	the	_
89-23	16158-16163	input	_
89-24	16164-16167	for	_
89-25	16168-16181	cross-subject	_
89-26	16182-16192	statistics	_
89-27	16193-16194	.	_

90-1	16195-16209	Identification	_
90-2	16210-16212	of	_
90-3	16213-16227	task-modulated	_
90-4	16228-16236	networks	_
90-5	16237-16239	To	_
90-6	16240-16248	identify	_
90-7	16249-16263	task-modulated	_
90-8	16264-16272	networks	_
90-9	16273-16275	in	_
90-10	16276-16288	ICA-analysis	_
90-11	16289-16291	of	_
90-12	16292-16296	task	_
90-13	16297-16301	fMRI	_
90-14	16302-16306	data	_
90-15	16307-16308	,	_
90-16	16309-16311	we	_
90-17	16312-16321	regressed	_
90-18	16322-16325	the	_
90-19	16326-16338	run-specific	_
90-20	16339-16347	activity	_
90-21	16348-16352	time	_
90-22	16353-16360	courses	_
90-23	16361-16364	for	_
90-24	16365-16369	each	_
90-25	16370-16377	network	_
90-26	16378-16385	against	_
90-27	16386-16389	the	_
90-28	16390-16393	run	_
90-29	16394-16396	's	_
90-30	16397-16407	respective	_
90-31	16408-16419	task-design	_
90-32	16420-16426	matrix	_
90-33	16427-16432	using	_
90-34	16433-16436	the	_
90-35	16437-16444	fsl_glm	_
90-36	16445-16452	utility	_
90-37	16453-16454	.	_

91-1	16455-16459	This	_
91-2	16460-16468	approach	_
91-3	16469-16480	essentially	_
91-4	16481-16488	answers	_
91-5	16489-16492	the	_
91-6	16493-16501	question	_
91-7	16502-16504	of	_
91-8	16505-16512	whether	_
91-9	16513-16514	a	_
91-10	16515-16522	network	_
91-11	16523-16525	is	_
91-12	16526-16530	more	_
91-13	16531-16537	active	_
91-14	16538-16540	in	_
91-15	16541-16544	one	_
91-16	16545-16549	task	_
91-17	16550-16559	condition	_
91-18	16560-16561	,	_
91-19	16562-16564	by	_
91-20	16565-16573	allowing	_
91-21	16574-16576	us	_
91-22	16577-16579	to	_
91-23	16580-16589	determine	_
91-24	16590-16593	the	_
91-25	16594-16597	fit	_
91-26	16598-16605	between	_
91-27	16606-16609	the	_
91-28	16610-16617	network	_
91-29	16618-16629	time-course	_
91-30	16630-16633	and	_
91-31	16634-16638	task	_
91-32	16639-16645	design	_
91-33	16646-16649	for	_
91-34	16650-16654	each	_
91-35	16655-16658	run	_
91-36	16659-16660	.	_

92-1	16661-16666	After	_
92-2	16667-16676	combining	_
92-3	16677-16680	the	_
92-4	16681-16685	beta	_
92-5	16686-16695	estimates	_
92-6	16696-16699	and	_
92-7	16700-16708	variance	_
92-8	16709-16713	from	_
92-9	16714-16718	each	_
92-10	16719-16729	regression	_
92-11	16730-16735	using	_
92-12	16736-16737	a	_
92-13	16738-16743	fixed	_
92-14	16744-16751	effects	_
92-15	16752-16760	approach	_
92-16	16761-16763	to	_
92-17	16764-16770	obtain	_
92-18	16771-16772	a	_
92-19	16773-16779	single	_
92-20	16780-16789	parameter	_
92-21	16790-16798	estimate	_
92-22	16799-16802	per	_
92-23	16803-16810	subject	_
92-24	16811-16814	and	_
92-25	16815-16824	component	_
92-26	16825-16826	,	_
92-27	16827-16829	we	_
92-28	16830-16835	could	_
92-29	16836-16845	determine	_
92-30	16846-16851	which	_
92-31	16852-16862	components	_
92-32	16863-16867	were	_
92-33	16868-16878	relatively	_
92-34	16879-16883	more	_
92-35	16884-16890	active	_
92-36	16891-16897	during	_
92-37	16898-16900	IN	_
92-38	16901-16907	blocks	_
92-39	16908-16916	compared	_
92-40	16917-16919	to	_
92-41	16920-16923	OUT	_
92-42	16924-16930	blocks	_
92-43	16931-16934	and	_
92-44	16935-16945	visa-versa	_
92-45	16946-16951	using	_
92-46	16952-16962	one-sample	_
92-47	16963-16970	t-tests	_
92-48	16971-16972	.	_

93-1	16973-16978	Since	_
93-2	16979-16987	contrast	_
93-3	16988-16997	estimates	_
93-4	16998-17001	for	_
93-5	17002-17005	the	_
93-6	17006-17014	relative	_
93-7	17015-17025	comparison	_
93-8	17026-17028	of	_
93-9	17029-17032	the	_
93-10	17033-17036	two	_
93-11	17037-17047	conditions	_
93-12	17048-17049	(	_
93-13	17050-17053	i.e	_
93-14	17054-17055	.	_

94-1	17056-17059	OUT	_
94-2	17060-17061	>	_
94-3	17062-17064	IN	_
94-4	17065-17066	,	_
94-5	17067-17069	IN	_
94-6	17070-17071	>	_
94-7	17072-17075	OUT	_
94-8	17076-17077	)	_
94-9	17078-17084	differ	_
94-10	17085-17089	only	_
94-11	17090-17092	in	_
94-12	17093-17097	sign	_
94-13	17098-17099	,	_
94-14	17100-17107	t-tests	_
94-15	17108-17112	were	_
94-16	17113-17119	set-up	_
94-17	17120-17124	such	_
94-18	17125-17129	that	_
94-19	17130-17138	positive	_
94-20	17139-17145	values	_
94-21	17146-17155	indicated	_
94-22	17156-17159	the	_
94-23	17160-17166	degree	_
94-24	17167-17169	to	_
94-25	17170-17175	which	_
94-26	17176-17179	the	_
94-27	17180-17187	network	_
94-28	17188-17191	was	_
94-29	17192-17202	relatively	_
94-30	17203-17207	more	_
94-31	17208-17214	active	_
94-32	17215-17221	during	_
94-33	17222-17225	the	_
94-34	17226-17228	IN	_
94-35	17229-17238	condition	_
94-36	17239-17240	,	_
94-37	17241-17246	while	_
94-38	17247-17255	negative	_
94-39	17256-17262	values	_
94-40	17263-17272	indicated	_
94-41	17273-17276	the	_
94-42	17277-17283	degree	_
94-43	17284-17286	to	_
94-44	17287-17292	which	_
94-45	17293-17296	the	_
94-46	17297-17304	network	_
94-47	17305-17308	was	_
94-48	17309-17319	relatively	_
94-49	17320-17324	more	_
94-50	17325-17331	active	_
94-51	17332-17338	during	_
94-52	17339-17342	the	_
94-53	17343-17346	OUT	_
94-54	17347-17356	condition	_
94-55	17357-17358	.	_

95-1	17359-17362	The	_
95-2	17363-17371	p-values	_
95-3	17372-17376	were	_
95-4	17377-17384	further	_
95-5	17385-17395	Bonferroni	_
95-6	17396-17405	corrected	_
95-7	17406-17407	,	_
95-8	17408-17413	which	_
95-9	17414-17421	limited	_
95-10	17422-17425	the	_
95-11	17426-17432	number	_
95-12	17433-17435	of	_
95-13	17436-17444	networks	_
95-14	17445-17449	only	_
95-15	17450-17452	to	_
95-16	17453-17458	those	_
95-17	17459-17463	that	_
95-18	17464-17468	most	_
95-19	17469-17477	strongly	_
95-20	17478-17492	differentiated	_
95-21	17493-17496	the	_
95-22	17497-17500	two	_
95-23	17501-17505	task	_
95-24	17506-17516	conditions	_
95-25	17517-17518	.	_

96-1	17519-17529	Components	_
96-2	17530-17535	which	_
96-3	17536-17540	were	_
96-4	17541-17554	significantly	_
96-5	17555-17565	associated	_
96-6	17566-17570	with	_
96-7	17571-17574	the	_
96-8	17575-17579	task	_
96-9	17580-17584	were	_
96-10	17585-17589	used	_
96-11	17590-17592	to	_
96-12	17593-17600	compare	_
96-13	17601-17608	spatial	_
96-14	17609-17620	differences	_
96-15	17621-17623	in	_
96-16	17624-17631	network	_
96-17	17632-17642	functional	_
96-18	17643-17655	connectivity	_
96-19	17656-17662	across	_
96-20	17663-17666	the	_
96-21	17667-17671	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder
96-22	17672-17675	and	_
96-23	17676-17682	noPTSD	_
96-24	17683-17689	groups	_
96-25	17690-17691	.	_

97-1	17692-17702	Functional	_
97-2	17703-17715	connectivity	_
97-3	17716-17718	of	_
97-4	17719-17733	task-modulated	_
97-5	17734-17742	networks	_
97-6	17743-17748	Group	_
97-7	17749-17760	differences	_
97-8	17761-17768	between	_
97-9	17769-17775	noPTSD	_
97-10	17776-17779	and	_
97-11	17780-17784	PTSD	_
97-12	17785-17789	were	_
97-13	17790-17798	assessed	_
97-14	17799-17802	for	_
97-15	17803-17806	the	_
97-16	17807-17815	networks	_
97-17	17816-17820	that	_
97-18	17821-17825	were	_
97-19	17826-17836	determined	_
97-20	17837-17839	to	_
97-21	17840-17842	be	_
97-22	17843-17856	significantly	_
97-23	17857-17871	task-modulated	_
97-24	17872-17873	,	_
97-25	17874-17885	constrained	_
97-26	17886-17888	to	_
97-27	17889-17895	voxels	_
97-28	17896-17902	within	_
97-29	17903-17904	a	_
97-30	17905-17914	binarized	_
97-31	17915-17919	mask	_
97-32	17920-17930	containing	_
97-33	17931-17939	positive	_
97-34	17940-17946	values	_
97-35	17947-17948	.	_

98-1	17949-17951	We	_
98-2	17952-17956	used	_
98-3	17957-17971	non-parametric	_
98-4	17972-17983	Monte-Carlo	_
98-5	17984-17989	based	_
98-6	17990-18001	permutation	_
98-7	18002-18009	testing	_
98-8	18010-18014	with	_
98-9	18015-18021	10,000	_
98-10	18022-18034	permutations	_
98-11	18035-18038	and	_
98-12	18039-18044	alpha	_
98-13	18045-18046	=	_
98-14	18047-18051	0.05	_
98-15	18052-18053	.	_

99-1	18054-18062	Clusters	_
99-2	18063-18065	of	_
99-3	18066-18076	activation	_
99-4	18077-18081	were	_
99-5	18082-18091	estimated	_
99-6	18092-18097	using	_
99-7	18098-18112	threshold-free	_
99-8	18113-18120	cluster	_
99-9	18121-18132	enhancement	_
99-10	18133-18134	(	_
99-11	18135-18139	TFCE	_
99-12	18140-18141	)	_
99-13	18142-18146	with	_
99-14	18147-18148	a	_
99-15	18149-18157	variance	_
99-16	18158-18167	smoothing	_
99-17	18168-18174	factor	_
99-18	18175-18177	of	_
99-19	18178-18179	5	_
99-20	18180-18182	mm	_
99-21	18183-18184	.	_

100-1	18185-18189	This	_
100-2	18190-18199	procedure	_
100-3	18200-18208	corrects	_
100-4	18209-18212	for	_
100-5	18213-18216	the	_
100-6	18217-18228	family-wise	_
100-7	18229-18234	error	_
100-8	18235-18239	rate	_
100-9	18240-18241	.	_

101-1	18242-18255	Mean-centered	_
101-2	18256-18259	age	_
101-3	18260-18263	and	_
101-4	18264-18267	ASI	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
101-5	18268-18272	drug	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
101-6	18273-18276	use	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
101-7	18277-18285	severity	http://maven.renci.org/NeuroBridge/neurobridge#AddictionSeverityIndex
101-8	18286-18292	scores	_
101-9	18293-18297	were	_
101-10	18298-18306	included	_
101-11	18307-18309	as	_
101-12	18310-18320	covariates	_
101-13	18321-18323	of	_
101-14	18324-18335	no-interest	_
101-15	18336-18337	.	_

102-1	18338-18349	Statistical	_
102-2	18350-18354	maps	_
102-3	18355-18359	were	_
102-4	18360-18368	rendered	_
102-5	18369-18373	onto	_
102-6	18374-18375	a	_
102-7	18376-18384	standard	_
102-8	18385-18388	MNI	_
102-9	18389-18394	brain	_
102-10	18395-18400	using	_
102-11	18401-18409	MRIcroGL	_
102-12	18410-18411	(	_
102-13	18412-18416	http	_
102-14	18417-18418	:	_
102-15	18419-18458	//www.mccauslandcenter.sc.edu/mricrogl/	_
102-16	18459-18460	)	_
102-17	18461-18462	.	_

103-1	18463-18476	Probabilistic	_
103-2	18477-18487	anatomical	_
103-3	18488-18494	labels	_
103-4	18495-18498	for	_
103-5	18499-18506	cluster	_
103-6	18507-18513	maxima	_
103-7	18514-18518	were	_
103-8	18519-18527	obtained	_
103-9	18528-18532	from	_
103-10	18533-18536	the	_
103-11	18537-18551	Harvard-Oxford	_
103-12	18552-18560	Cortical	_
103-13	18561-18564	and	_
103-14	18565-18576	Subcortical	_
103-15	18577-18584	atlases	_
103-16	18585-18586	,	_
103-17	18587-18595	reported	_
103-18	18596-18598	in	_
103-19	18599-18607	standard	_
103-20	18608-18611	MNI	_
103-21	18612-18617	space	_
103-22	18618-18619	.	_

